Novel pyrrolo pyrimidine derivatives

专利摘要:
The present invention describes new pyrrolo pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel pyrrolo pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
公开号:AU2012282229A1
申请号:U2012282229
申请日:2012-07-07
公开日:2014-01-16
发明作者:Richard Heng；Elizabeth Kate Hoegenauer；Guido Koch；Robert Alexander Pulz；Anna Vulpetti；Rudolf Waelchli
申请人:Novartis AG；
IPC主号:C07D487-04

专利说明:
WO 2013/008095 PCT/IB2012/001699 Novel Pyrrolo Pyrimidine Derivatives The present invention describes new pyrrolo pyrimidine derivatives that are good drug candidates. The compounds of the present invention may generally exhibit a selective inhibition of Bruton's tyrosine kinase (Btk). Background of the invention The essential role of Btk in autoimmune disease is underlined by the observations that Btk-deficient mice are protected in standard preclinical models for rheumatoid arthritis (Jansson and Holmdahl, 1993), systemic lupus erythematosus (Steinberg,B.J. et al., J. Clin. Invest, 70, 587-597, 1982), as well as allergic disease and anaphylaxis (Hata,D. et al., J. Exp. Med. 187, 1235-1247, 1998). In addition, many cancers and lymphomas express Btk and appear to be dependent on Btk function (DavisR.E. et al., Nature, 463, 88-92, 2010). Therefore, inhibition of Btk activity may be useful in the treatment of immune disorders such as rheumatoid arthritis, systemic lupus erythematosus, allergic diseases, anaphylaxis and inflammatory conditions. Moreover, inhibition of Btk may be useful in the treatment of cancers of haematopoietic origin including chronic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma and other B cell lymphomas. The compounds of the present invention may therefore potentially be useful in the treatment of a wide range of disorders, particularly Btk-related diseases or disorders, and may for example be useful in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, or cancers e.g. of hematopoietic origin or solid tumors.
WO 2013/008095 PCT/IB2012/001699 -2 More particularly, the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; R5 0 R3 N R2 R4' R2 R1 X-R10 N N H wherein, R1 is hydrogen, C1-C6 alkyl optionally substituted by hydroxy; R2 is hydrogen or halogen; R3 is hydrogen or halogen; R4 is hydrogen, R5 is phenyl optionally substituted by halogen; SF 5 ; NR6R7; hydroxy; C1-C6 alkoxy; C1 C6 alkenyl; C1-C6 alkyl carbonyl; C1-C6 alkyl optionally substituted by hydroxy, halogen, or C1-C6 alkoxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, or C1-C6 alkyl optionally substituted by halogen; or R5 is a 4 - 14 membered mono- or bicyclic heterocyclyl or heteroaryl ring system comprising 1, 2 or 3 heteroatoms selected from N, S and 0 that ring being optionally substituted by halogen; hydroxy; C1-C6 alkoxy optionally substituted by hydroxy or halogen; or C1-C6 alkyl optionally substituted by hydroxy or halogen; or R4 and R5 together with the atoms to which they are bound form a piperidone ring, optionally comprising an annulated phenyl ring, any such ring being optionally substituted by C1-C6 alkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl each of which substitution member may optionally be substituted by halogen or hydroxy; R6 and R7 are independently selected from hydrogen or C1-C6 alkyl; or R6 and R7 together with the nitrogen atom to which they are bound form a 4 - 8 membered saturated azacycloalkane ring, optionally substituted by halogen, hydroxy or C1-C6 alkyl; O (CH2 )q X is 0, S(O), wherein n is 0, 1 or 2, or 0 wherein q is 2 or 3, and R10 is absent; WO 2013/008095 PCT/IB2012/001699 -3 or X is CH or N; and R10 is hydrogen, hydroxy, -NR6R7, -CO-R11, -S(O)p-R12 wherein p is 1 or 2, R 11 is C1-C6 alkyl optionally substituted by hydroxy, cyano, halogen, carboxy or C1-C6 alkoxy carbonyloxy; or NR6R7; and R12 is C1-C6 alkyl or NR6R7. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen, R5 is phenyl substituted by halogen; C1-C6 alkoxy or C1-C6 alkyl optionally substituted by halogen or hydroxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, C1-C6 alkyl optionally substituted by halogen; X is 0, S(O), wherein n is 0, 1 or 2, or O (CH2 )q 0 wherein q is 2 or 3, and R10 is absent; and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy; X is 0, S(O), wherein n is 0, 1 or 2, or O (CH2 )q 0 wherein q is 2 or 3, and R10 is absent; and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen, R5 is phenyl substituted by halogen; C1-C6 alkoxy; C1-C6 alkyl optionally substituted by halogen or hydroxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, or C1 C6 alkyl optionally substituted by halogen; X stands for 0 and R10 is absent; or X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined above.
WO 2013/008095 PCT/IB2012/001699 -4 In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen; R5 is phenyl substituted by C1-C6 alkoxy; C1-C6 alkyl optionally substituted by halogen or hydroxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, or C1-C6 alkyl optionally substituted by halogen; X stands for N, R10 is hydrogen or -CO-R1 1, R11 stands for NR6R7 wherein R6 and R7 are independently hydrogen or methyl; and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen, R5 is azetidine optionally substituted by C1-C6 alkoxy, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy in the 6-position of said isoquinolin-ring, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen, R5 is WO 2013/008095 PCT/IB2012/001699 -5 azetidine optionally substituted by C1-C6 alkoxy, X stands for 0, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy, X stands for 0, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy in the 6-position of said isoquinolin-ring, X stands for 0, and the remaining variables are as defined above. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently from each other selected from hydrogen and halogen, R4 is hydrogen, R5 is phenyl substituted one or more times by halogen, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted by hydroxy, X stands for 0 or S, and R10 is absent. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is methyl or hydroxymethyl , R2 and R3 are independently from each other selected from hydrogen and halogen, R4 is hydrogen, R5 is phenyl substituted one or more times by halogen, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted by hydroxy, X stands for N, R10 is hydrogen or -CO-R1 1, and R11 is NR6R7 wherein R6 and R7 are independently selected from C1
C
6 -alkyl.
WO 2013/008095 PCT/IB2012/001699 -6 With regard to a compound of formula (1) the following significances represent further embodiments of the invention independently, collectively or in any combination or in any sub-combination thereof: 1. R1 is hydrogen, methyl or hydroxymethyl; 2. R1 is methyl or hydroxymethyl; 3. R2 and R3 are independently hydrogen or fluoro; 4. R1 is methyl or hydroxymethyl and R2 and R3 are independently hydrogen or fluoro; 5. R4 is hydrogen; 6. R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy; 7. R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy in the 6 position of the 3,4-dihydro-2H-isoquinolin-1 -one ring; 8. R5 is phenyl optionally substituted by -NR6R7, halogen; C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, or C1-C6 alkyl optionally substituted by halogen or hydroxy; 9. R5 is phenyl substituted by -NR6R7, halogen, C1-C6 alkoxy or C1-C6 alkyl optionally substituted by halogen or hydroxy; 10. R5 is phenyl substituted by halogen, C1-C6 alkoxy, C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by fluoro or hydroxy; 11. R5 is a 4-, 5-, 6-, or 7-membered monocyclic heterocycle, or a 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic heterocycle comprising 1, 2 or 3 heteroatoms selected from N, S and 0 that ring being optionally substituted by halogen; hydroxy; C1-C6 alkoxy optionally substituted by hydroxy or halogen; or C1-C6 alkyl optionally substituted by hydroxy or halogen; 12. R5 is a 4-, 5-, 6-, or 7-membered monocyclic heterocycle comprising 1 or 2 heteroatoms selected from N, S and 0 that ring being optionally substituted by halogen; hydroxy; C1-C6 alkoxy optionally substituted by hydroxy or halogen; or C1-C6 alkyl optionally substituted by hydroxy or halogen; 13. R5 is azetidine substituted by C1-C6 alkoxy or C1-C6 alkyl; WO 2013/008095 PCT/IB2012/001699 -7 14. X is 0 and R10 is absent or is N and R10 is H or CO-R1 1; 15. X is 0 and R10 is absent or is N and R10 is CO-R11; 16. X is 0 and R10 is absent; 17. X is N and R10 is CO-R11; 18. R11 is NR6R7 and R6 and R7 are independently selected from hydrogen or C1 C6 alkyl; 19. R11 is NR6R7 and R6 and R7 are independently selected from C1-C6 alkyl; 20. R11 is NR6R7 and R6 and R7 are independently selected from C1-C3 alkyl; 21. R11 is NR6R7 and R6 and R7 are methyl. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof for use as a medicament. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof for use in the treatment of a disease or disorder mediated by Btk. In another embodiment the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof, which is selected from: 4-(4-{5-Fluoro-3-[4-(1 -fluoro-cyclopropyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[(3,3-Dimethyl-2,3-d ihydro-benzofuran-6-carbonyl)-amino]-5-fluoro-2-methyl phenyl}-7H-pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[(5-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-2-carbonyl) amino]-phenyl}-7H-pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-isopropyl-methyl-amino)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 3-Methyl-1 H-indole-6-carboxylic acid {3-[6-(1 -dimethylcarbamoyl-1,2,3,6-tetrahydro pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-amide, WO 2013/008095 PCT/IB2012/001699 -8 4-(4-{5-Fluoro-3-[4-(2-hydroxy-1,1 -dimethyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-2-methyl-3-(4-piperidin-1-yl-benzoylamino)-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-3-(isopropenyl-benzoylamino)-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[4-(1 -trifluoromethyl-cyclopropyl)-benzoylamino]-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-3-(4-isopropoxy-benzoylamino)-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-pentafluorothio-benzoylamino]-2-methyl-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3, 6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-(2-methoxy-1,1-dimethyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-(1-methoxy-1-methyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 1-Methyl-1 H-pyrrolo[2,3-b]pyridine-6-carboxylic acid {3-[6-(1-dimethyl-carbamoyl-1,2,3,6 tetrahyd ro-pyrid in-4-yl)-7 H-pyrrolo[2,3-d]pyrimid in-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-{4-[3-(4-Dimethylamino-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylamino]-2-hydroxymethyl-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-2-hydroxymethyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)-benzoylamino] phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Acetyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6 yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-4-fluoro-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl} 3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{4-Fluoro-3-[4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoylamino]-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, WO 2013/008095 PCT/IB2012/001699 -9 N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimid in-4-yl]-5-fluoro-2-methyl phenyl}-2-fluoro-4-(1 -hydroxy-1 -methyl-ethyl)-benzamide, N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimid in-4-yl]-2-hyd roxymethyl phenyl}-2-fluoro-4-(1 -hydroxy-1 -methyl-ethyl)-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-d ihydro-2 H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimid in-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(3,6-dihydro-1 -oxido-2 H-thiopyran-4-yl)-7H pyrrolo[2,3-d] pyrimid in-4-yl]-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-1,1 -dioxido-2 H-thiopyran-4-yl)-7H-pyrrolo[2,3 d] pyrim id in-4-yl]-5-fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1,4-d ioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hyd roxy-cyclohex- 1 -enyl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl] 2-methyl-phenyl}-benzamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2'3 d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-Cyclopropyl-N-(5-fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-phenyl)-benzamide, Acetic acid 2-(4-{4-[3-(4-cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridin-1-yl)-2-oxo-ethyl ester, 4-Cyclopropyl-N-(5-fluoro-3-{6-[1-(2-hydroxy-actyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H pyrrolo[2,3-d] pyrimid in-4-yl}-2-methyl-phenyl)benzamide, N-(3-{6-[1-(2-Cyano-acetyl)-1,2,3, 6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4 yl}-5-fluoro-2-methyl-phenyl)-4-cyclopropyl-benzamide, N-(5-Fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H pyrrolo[2,3-d]pyrimidin-4-yl}-phenyl)-4-(pentafluoro-sulfanyl)-benzamide, Acetic acid 2-[4-(4-{5-fluoro-2-methyl-3-[4-(pentafluoro-sulfanyl)-benzoylam ino]-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridin-1-yl]-2-oxo-ethyl ester, N-(5-Fluoro-3-{6-[1-(2-hydroxy-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3 d] pyrimid in-4-yl}-2-methyl-phenyl)-4-(pentafluoro-sulfanyl)-benzamide, 4-{4-[3-(4-tert-Butyl-benzoylamino)-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester, 4-tert-Butyl-N-(3-{6-[1-(2-fluoro-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3 d]pyrimidin-4-yl}-2-hydroxymethyl-phenyl)-benzamide, WO 2013/008095 PCT/IB2012/001699 - 10 4-(4-{5-Fluoro-3-[2-fluoro-4-(1 -hydroxy-1 -methyl-ethyl)-benzoylamino]-2-methyl-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-phenyl}-benzamide, 4-{4-[3-(4-tert-Butyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin 6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{5-fluoro-3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yl]-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1-dimethylsulfamoyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-2-methyl-phenyl}-benzamide, 4-{4-[3-(6-tert-Butyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl] 7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{2-Hydroxymethyl-3-[6-(1-hydroxy-1-methyl-ethyl)-1-oxo-3,4-dihydro-1 H-isoquinolin 2-yl]-phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hydroxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro 2-methyl-phenyl}-benzamide, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl phenyl}-4-dimethylamino-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl -N-{2-methyl-3-[6-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-phenyl}-benzamide, 4-tert-Butyl -N-{3-[6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-2-methyl-phenyl}-benzamide, WO 2013/008095 PCT/IB2012/001699 - 11 4-tert-Butyl-N-{3-[6-(1,4-d ioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl]-2 hyd roxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex- 1 -enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hyd roxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1 -enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hyd roxymethyl-phenyl}-benzamide, 4-(4-{3-[(3-tert-Butoxy-azetid ine- 1 -carbonyl)-amino]-5-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[(3-isopropoxy-azetidine-1-carbonyl)-amino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 5-Fluoro-1,3-dihydro-isoindole-2-carboxylic acid {3-[6-(1-dimethylcarbamoyl-1,2,3,6 tetrahyd ro-pyrid in-4-yl)-7 H-pyrrolo[2,3-d]pyrimid in-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-[4-(5-Fluoro-2-methyl-3-{[3-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-azetidine-1 carbonyl]-amino}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2 H-pyridine-1 carboxylic acid dimethylamide, 3-tert-Butoxy-azetidine-1-carboxylic acid {3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-amino]-4-fluoro-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-amino]-4-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, and 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide. As used herein, the term "alkyl" refers to a fully saturated branched or unbranched hydrocarbon moiety having up to 20 carbon atoms. Unless otherwise provided, alkyl refers to hydrocarbon moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Representative examples of alkyl include, but WO 2013/008095 PCT/IB2012/001699 - 12 are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3 dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like. As used herein, the term "alkenyl" refers to an unsaturated branched or unbranched hydrocarbon moiety having 2 to 20 carbon atoms. It comprises 2 to 20 carbon atoms, Unless otherwise provided, alkenyl refers to moieties having 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 7 carbon atoms, or 2 to 4 carbon atoms. Representative examples of alkenyl include, but are not limited to, ethenyl, n-propenyl, iso-propenyl, n butenyl, sec-butenyl, iso-butenyl, tert-butenyl, n-pentenyl, isopentenyl, neopentenyl, n hexenyl, 3-methylhexenyl, 2,2- dimethylpentenyl, 2,3-dimethylpentenyl, n-heptenyl, n octenyl, n-nonenyl, n-decenyl and the like. As used herein, the term "alkoxy" refers to alkyl-O-, wherein alkyl is defined herein above. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like. Typically, alkoxy groups have about 1-7, more preferably about 1-4 carbons. As used herein, the term "cycloalkyl" refers to saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups of 3-12 carbon atoms. Unless otherwise provided, cycloalkyl refers to cyclic hydrocarbon groups having between 3 and 9 ring carbon atoms or between 3 and 7 ring carbon atoms. Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl and cyclohexenyl and the like. Exemplary bicyclic hydrocarbon groups include bornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6 dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl and the like. Exemplary tricyclic hydrocarbon groups include adamantyl and the like. As used herein, the term "azacycloalkane" refers to saturated or unsaturated monocyclic, bicyclic or tricyclic hydrocarbon groups of 3-12 carbon atoms as defined for "cycloalkyl", wherein one carbon atom is replaced by a nitrogen atom. Unless otherwise provided, azacycloalkyl refers to cyclic aza-hydrocarbon groups having between 2 and 9 ring carbon atoms and one nitrogen atom or between 2 and 7 ring carbon atoms and WO 2013/008095 PCT/IB2012/001699 - 13 one nitrogen atom. Exemplary monocyclic aza-hydrocarbon groups include, but are not limited to, aziridinyl, azetidinly, pyrollidinyl, piperidinyl, azepanyl, dihydroazepinyl and the like. As used herein, the term "halogen" or "halo" refers to fluoro, chloro, bromo, and iodo. As used herein the term "heterocyclic", "heterocyclyl" or "heterocyclo" may refer to a saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system and contains at least one heteroatom selected from 0, S and N, where the N and S can also optionally be oxidized to various oxidation states. The heterocyclic group can be attached at a heteroatom or a carbon atom. The heterocyclyl may include fused or bridged rings as well as spirocyclic rings. Examples of heterocycles include azetidine, tetrahydrofuran (THF), dihydrofuran, 1, 4 dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, and the like. As used herein, the term "aryloxy" refers to both an -0-aryl and an -0-heteroaryl group, wherein aryl and heteroaryl are defined herein. As used herein, the term "heteroaryl" refers to a 5-14 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to 8 heteroatoms selected from N, 0 or S. Typically, the heteroaryl is a 5-10 membered ring system (e.g., 5-7 membered monocycle or an 8-10 memberred bicycle) or a 5-7 membered ring system. Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5 imidazolyl, 3-, 4-, or 5- pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5 oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2, 3-triazolyl, tetrazolyl, 2 , 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, or 5 pyrimidinyl. The term "heteroaryl" also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include 1-, 2-, 3-, 5-, 6-, 7-, or 8- indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3- WO 2013/008095 PCT/IB2012/001699 - 14 , 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8- purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9 quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3- , 5-, 6-, 7-, or 8 quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1- , 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10 phenathrolinyl, 1-, 2- , 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10 phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenoxazinyl, 2-, 3-, 4-, 5-, 6-, or I-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10- benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6 , 7-, 8-, 9-, 10 -, or 11-7H-pyrazino[2,3-c]carbazolyl,2-, 3-, 5-, 6-, or 7-2H- furo[3,2-b] pyranyl, 2-, 3-, 4-, 5-, 7-, or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1H-pyrazolo[4,3-d] oxazolyl, 2-, 4-, or 54H-imidazo[4,5-d] thiazolyl, 3-, 5-, or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6- imidazo[2,1-b] thiazolyl, 1-, 3-, 6-, 7-, 8-, or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10, or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or 7-imidazo[1 2 b][1 ,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5- , 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7 benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9 benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11 1 H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroary groups include, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5- , 6-, or 7 benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-, or 7-benzothiazolyl. As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. "Salts" include in particular "pharmaceutical acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, WO 2013/008095 PCT/IB2012/001699 -15 bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine. The pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a WO 2013/008095 PCT/IB2012/001699 - 16 stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11c, 13c, 14c, 1 5 N, 1 8 F 31 p, 32 p, 35 S 31CI, 1251 respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14C, or those into which non-radioactive isotopes, such as 2 H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2 H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (1) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed. Further, substitution with heavier isotopes, particularly deuterium (i.e., 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (1). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The WO 2013/008095 PCT/IB2012/001699 - 17 term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, d 6 acetone, d 6 -DMSO. Compounds of the invention, i.e. compounds of formula (1) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (1) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (1) with the co-crystal former under crystallization conditions and isolating co crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (1). As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
WO 2013/008095 PCT/IB2012/001699 - 18 The term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by Btk, or (ii) associated with Btk activity, or (iii) characterized by activity (normal or abnormal) of Btk; or (2) reducing or inhibiting the activity of Btk; or (3) reducing or inhibiting the expression of Btk. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of Btk; or reducing or inhibiting the expression of Btk partially or completely. As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human. As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process. As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers WO 2013/008095 PCT/IB2012/001699 - 19 to preventing or delaying the onset or development or progression of the disease or disorder. As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment. As used herein, the term "a," "an," "the" and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (RS)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form. Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
WO 2013/008095 PCT/IB2012/001699 - 20 Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0,O'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent. Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water. The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs. In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as WO 2013/008095 PCT/IB2012/001699 - 21 adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Tablets may be either film coated or enteric coated according to methods known in the art. Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium WO 2013/008095 PCT/IB2012/001699 - 22 stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient. Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
WO 2013/008095 PCT/IB2012/001699 - 23 As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant. The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs. The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc. The compounds of formula I in free form or in salt form, exhibit valuable pharmacological properties, e.g. Btk modulating properties, e.g. as indicated by in vitro and in vivo tests as provided in the next sections and are therefore indicated for therapy. Compounds of the invention may be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; WO 2013/008095 PCT/IB2012/001699 - 24 including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjdgren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; leukemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstroem disease. Thus, as a further embodiment, the present invention provides the use of a compound of formula (1) or a salt thereof in therapy. In a further embodiment, the therapy is selected from a disease which may be treated by inhibition of Btk. In another embodiment, the disease is selected from the afore-mentioned list, suitably rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjdgren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, atopic dermatitis, allergic rhinitis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, morbus Crohn, Goodpasture's syndrome, Grave's disease, antibody-mediated transplant rejection (AMR), B cell-mediated hyperacute, acute and chronic transplant rejection; multiple myeloma; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; myelofibrosis with myeloid metaplasia; and Waldenstroem disease, more suitably rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), systemic lupus erythematosus, multiple sclerosis, Sjdgren's syndrome, chronic autoimmune urticaria, atopic dermatitis, allergic WO 2013/008095 PCT/IB2012/001699 - 25 rhinitis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, multiple myeloma; non-Hodgkin lymphoma. In another embodiment, the invention provides a method of treating a disease which is treated by inhibition of Btk kinase comprising administration of a therapeutically acceptable amount of a compound of formula (1) or a salt thereof. In a further embodiment, the disease is selected from the afore-mentioned list, suitably rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjdgren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, atopic dermatitis, allergic rhinitis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, morbus Crohn, Goodpasture's syndrome, Grave's disease, antibody-mediated transplant rejection (AMR), B cell-mediated hyperacute, acute and chronic transplant rejection; multiple myeloma; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; myelofibrosis with myeloid metaplasia; and Waldenstroem disease, more suitably rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), systemic lupus erythematosus, multiple sclerosis, Sjdgren's syndrome, chronic autoimmune urticaria, atopic dermatitis, allergic rhinitis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, multiple myeloma; non-Hodgkin lymphoma. Methods of synthesizing Pyrrolo-pyrimidines Agents of the invention, i.e. compounds in accordance to the definition of formula (1), may be prepared by a reaction sequence (shown below) involving Suzuki coupling of a protected boronic esters II with the corresponding aryl halides l', conveniently furnishing intermediate Ill. Deprotection of 11, e.g. with diluted hydrochloric acid in methanol or the like and acylation, e.g. with an appropriate acetylating agent, e.g. unsubstituted or substituted acetanhydride in the absence or presence of a solvent, of IV is followed by an additional Suzuki coupling with boronic ester VI and acylation of VII (optionally followed by a deprotection step), as shown in Reaction Scheme 1 below, wherein X denotes N, and the group PG refers to a protecting group such as for example, tert- WO 2013/008095 PCT/IB2012/001699 - 26 butyloxycarbonyl, that may be easily removed e.g. by diluted hydrochloric acid in methanol or the like. Reaction Scheme 1: CI CI N N Suzuki coupling 1+B X-PG _ _ _ N- / X-PG N N 0NN H H Il' II ||| Deprotection CI CI X-R10 : Acylation N XH N N N N H H IV V R3 R2
NH
2 Suzuki coupling R1 O' , ' VI R3 R5 0 R3 R2 NH 2 HN R2 R1 Acylation R1* R1 N X-R10 NX-1 N~ / X-RI N N N H N H VII Vill Alternatively, the compounds of formula (1) may also be prepared by a reaction sequence involving Suzuki coupling of boronic esters IX with the corresponding aryl halides 1', followed by an additional Suzuki coupling of V with boronic esters VI and an WO 2013/008095 PCT/IB2012/001699 - 27 acylation of VII (optionally followed by a deprotection step), as shown in Reaction Scheme 2 below: Reaction Scheme 2: CI CI N -0R Suzuki coupling N + B / X-RION R1 H H I' IX V R3 R2 1
NH
2 VI R1 B 1Suzuki coupling R5 O R3 R3 HN R2 R2 NH 2 RI Acylation R1 X-R10 N/X-R10 N N N N H H VIII VII Alternatively, the compounds of formula (1) may also be prepared by a reaction sequence involving Suzuki coupling of boronic esters VI with the corresponding aryl halides III, acylation of intermediate X, followed by deprotection of XI and acylation of XII (optionally followed by a deprotection step), as shown in Reaction Scheme 3 below, wherein X denotes N, and the group PG refers to a protecting group that may be easily removed, such as for example, tert-butyloxycarbonyl. Reaction Scheme 3: WO 2013/008095 PCT/IB2012/001699 -28 R3 CI R2 .NH 2 Suzuki coupling R N X-PG R1 KR3 N N R3 N H R2 , NH 2 X-PG III N R1 0B' VI Acylation R5 0 R3 R5 0 R3 HN R2 HN R2 Deprotection R1 R1 XH X-PG N N N N H H XII XI I Acylation R5 0 R3 HN R2 R1 X-R10 N N H VIII Alternatively, the compounds of formula (1) may also be prepared by a reaction sequence involving Suzuki coupling of boronic esters XIII with the corresponding aryl halides III, followed by deprotection of XI and acylation of XII (optionally followed by a deprotection step), as shown in Reaction Scheme 4 below, wherein X denotes N, and the group PG refers to a protecting group that may be easily removed, such as for example, tert-butyloxycarbonyl.
WO 2013/008095 PCT/IB2012/001699 - 29 Reaction Scheme 4: R5 0 R3 C1 HN R2 Suzuki coupling N X-PG R3 R1 N N H N H R2 N R5 N I X-PG III - 0N N O0 Xll Deprotection R5 0 R3 R5 0 R3 HN R2 HN R2 RI Acylation R1 X-R10 XH N N N N H H Vill xII Alternatively, the compounds of formula (1) may also be prepared by a Suzuki coupling of boronic esters XIV with the corresponding aryl halides III (optionally followed by a deprotection step), as shown in Reaction Scheme 5 below: Reaction Scheme 5: R3 R4 R5 0 R3 CI R2 N R5 R4'N R2 0 Suzuki coupling N /X-R10 + R1 R1 N N O.B,0 N H 0 0 N -I 111I X-R10 III N N xiv xv WO 2013/008095 PCT/IB2012/001699 - 30 Alternatively, the compounds of formula (1) may also be prepared by urea formation reaction of anilines Vil (optionally followed by a deprotection step), as shown in Reaction Scheme 6 below: Reaction Scheme 6: R3 R5 O R3 R2 NH 2 HN R2 R1 Urea formation aR1 N X-R10 N X-1 C/I X-RIO NN N N H N H Vil Vill Alternatively, the compounds of formula (1) may be prepared by a reaction sequence involving Suzuki coupling of boronic esters X111 with the corresponding aryl halides XVI. Protection of XVII is followed by halogenation XVII, deprotection of XIX, and Suzuki coupling of halide XX with boronic ester IX (optionally followed by a deprotection step), as shown in Reaction Scheme 7 below, wherein the group PG refers to a protecting group that may be easily removed, such as for example, benzenesulfonyl. Reaction Scheme 7: WO 2013/008095 PCT/IB2012/001699 - 31 R3 H R5 O R3 C1 R2 t N R5 HN R2 B R0 Suzuki coupling R N + R 1II R 1 N N B H 0 0 Nj XVI N N H X111 XVil IProtection R5 0 R3 R5 0 R3 HN R2 HN R2 RI IE Halogenation R R1 RI r B r N N PG PG XIX XVill I Deprotection R5 0 R3 R5 0 R3 HN R2 HN R2 Suzuki coupling R1 - R1 N N Br B X-R10 LX-R10 N N 0 NN H H XX IX Vill WO 2013/008095 PCT/IB2012/001699 - 32 Synthesis of the compound(s) of the invention: EXPERIMENTAL SECTION Abbreviations: AcOH Acetic acid BOC tert-Butyloxycarbonyl COMIU: (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino carbenium hexafluorophosphate Cs 2
CO
3 Cesium carbonate DCM: Dichloromethane DIPEA: Ethyl-diisopropyl-amine, Hunig's base, DIEA DMA: N,N-Dimethylacetamide DMAP: Dimethyl-pyridin-4-yl-amine DMF: N,N-Dimethyl formamide DMSO: Dimethylsulfoxide EtOAc: Acetic acid ethyl ester EtOH: Ethanol HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N',N' tetramethyluroniumhexafluorophosphat hrs: Hours LDA: Lithium diisopropyamide MeCN: Acetonitrile MeOH: Methanol NaBH 4 : Sodium borohydride NaH sodium hydride Na 2
SO
4 Sodium sulfate
NH
4 0H: Ammonia hydrogen solution 25 % Pd/C: Palladium on carbon Pd 2 (dba) 3 : Tris(dibenzylideneacetone)dipalladium(O) TEA: Triethylamine TFA: Trifluoro-acetic acid WO 2013/008095 PCT/IB2012/001699 -33 THF: Tetrahydrofuran rt: Retention time r.t. Room temperature Xantphos: 4,5-Bis-diphenylphosphanyl-9,9-dimethyl-9H-xanthene 1 H-NMR spectra were recorded on a Bruker 600 MHz, a Bruker 500 MHz, or a Bruker 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad) and number of protons. Electron Spray Ionization (ESI) mass spectra were recorded on an Agilent 1100 Series mass spectrometer. Mass spectrometry results are reported as the ratio of mass over charge. Detailed analytical HPLC chromatography methods referred to in the preparations and examples below are outlined as follows: Preparative LC/MS Method 1: Preparative Waters chromatography instrument equipped with a mircomass ZQ MS detector and Waters X bridge C18-ODB (5 pm) 30x15Omm column. Peak detection is reported at 210 nm wavelength. Solvent A: Water containing 1 mM ammonium hydrogen carbonate Solvent B: Acetonitrile containing 0.04% formic acid. Flow rate at 50 ml/minute Gradient: Time [minutes] Solvent A [%] Solvent B [%] 0 85 15 1 85 15 10 10 80 11 0 100 13.5 0 100 LC/MS Method 1: Waters Acquity UPLC instrument equipped with diode array detector, Waters SQD Single Stage Quadrupole mass spectrometer and Waters Acquity HSS T3 (1.8pm) 2.1x5Omm column. Peak detection is reported full scan 210 - 315 nm wavelength. Column temperature 50 C. Solvent A: Water containing 0.05% ammonium acetate and 0.05% formic acid.
WO 2013/008095 PCT/IB2012/001699 - 34 Solvent B: Acetonitrile containing 0.04% formic acid. Flow rate at 1.2 ml/minute Gradient: Time [minutes] Solvent A [%] Solvent B [%] 0 98 2 1.40 2 98 2.15 2 98 2.19 98 2 2.20 98 2 Mass range: ESI +/-: 120 - 1200 m/z All reagents, starting materials and intermediates utilized in these examples are available from commercial sources or are readily prepared by methods known to those skilled in the art.
WO 2013/008095 PCT/IB2012/001699 - 35 Example 1 4-(4-{5-Fluoro-3-[4-(1 -fluoro-cyclopropvl)-benzovlaminol-2-methyl-phenyl}-7H pyrrolo[2'3-dpyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide H F F N NN N 0 X N _ N N N H / (1) 4-(4-Chloro-7H- pyrrolo[2,3-d1pyrimidin-6-yl)-3,6-d ihydro-2 H-pyrid ine- 1 -carboxylic acid tert-butyl ester, Intermediate 1 CI N N N- N0 H To a mixture of 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine (2.6 g, 9.30 mmol) and dichlorobis(triphenylphosphine)palladium (II) (0.52 g, 0.74 mmol) in 1-propanol (120 ml) and aqueous sodium carbonate solution (2M, 10.23 ml, 20.46 mmol), 4-(4,4,5,5 tetramethyl-[1,2,3]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (3.02 g, 9.77 mmol) was added. The mixture was heated to 1000C for 18 hours. After cooling the brownish mixture was diluted with 200 ml water and extracted with DCM. The organic layer was washed with brine (2x) and dried over sodium sulfate, than filtered and evaporated. The residue was purified by flash chromatography on silica (cyclohexane/EtOAc 1:1) to afford the compound Intermediate 1 as a beige solid. MS (ESI): 335 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.64 (br s, 1H), 8.56 (s, 1H), 6.59 (s, 2H), 4.08 (br s, 2H), 3.57 (m, 2H), 2.55 (m, 2H), 1.45 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 36 (2) 4-Chloro-6-(1,2,3,6-tetrahyd ro-pyrid in-4-yl)-7H-pyrrolo[2,3-dipyrimid ine, Intermediate 2 CI N NH H To a solution of compound Intermediate 1 (2.60 g, 7.77 mmol) in 10 ml DCM, 30 ml TFA/water 95:5 were added. The resulting mixture was stirred at room temperature for 2 hours. The mixture was diluted with water and basified by addition of 2N sodium hydroxide and extracted with DCM. The organic layer was washed with brine (2x), dried over sodium sulfate and evaporated. The residue was purified by flash chromatography on silica (cyclohexane/EtOAc 1:1 to EtOAc) to afford the compound Intermediate 2 as a beige solid. MS (ESI): 235 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.70 (br s, 2H), 8.56 (s, 1H), 6.58 (s, 1 H), 6.55 (br s, 1 H), 3.80 (m, 2H), 3.30 (m, 2H), 2.80 (m, 2H). (3) 4-(4-Chloro-6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-d] pyrimidine, Intermediate 3 CI N[U N N N H / To a suspension of the amine Intermediate 2 (0.75 g, 3.20 mmol) in DCM (30 ml) and DIPEA (1.09 ml, 6.39 mmol), dimethylcarbamoylchloride (0.52 g, 4.79 mmol) was added. The mixture was stirred at room temperature for 20 hours. The solvents were evaporated under reduced pressure. The residue was purified by flash chromatography on silica (EtOAc to EtOAc/methanol/ammonia 95:5:0.5) to afford the compound Intermediate 3 as a beige solid. MS (ESI): 306 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.65 (s, 1H), 8.55 (s, 1H), 6.60 (s, 1H), 6.57 (s, 1H), 3.90 (m, 2H), 3.36 (m, 2H), 2.77 (s, 6H), 2.57 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 37 (4) 2-(Fluoro-2-methyl-3-nitro-phenyl)-4,4,5,5-tetramethyl-[1,3,21dioxaborolone, Intermediate 4 F B N ' I I 0 0 To a mixture of 1-Bromo-5-fluoro-2-methyl-3-nitro-benzene (5.0 g, 21.37 mmol) and bis(diphenylphosphino)ferrocenedichloropalladium (II) (0.78 g, 1.06 mmol) in 200 ml dioxane, bis-(pinacolato)-diboron (8.14 g, 32.0 mmol) and potassium acetate (7.34 g, 74.8 mmol) were added. The mixture was heated to 1000C for 6 hours. After cooling the brownish mixture was diluted with 200 ml water and extracted with EtOAc. The organic layer was washed with sodium hydrogen carbonate (1x) and brine (2x) and dried over sodium sulfate, then filtered and evaporated. The residue was purified by flash chromatography on silica (cyclohexane/EtOAc 9:1) to afford the compound Intermediate 4 as a yellow oil. MS (ESI): 281 [M]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 7.79 (d, 1H), 7.55 (d, 1H), 2.48 (s, 3H), 1.31 (s, 12H). (5) 5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,21dioxaborolan-2-vl)-phenylamine, Intermediate 5 F B NH 2 0 The nitro compound Intermediate 4 (12.4 g, 44.1 mmol) was dissolved in 300 ml EtOAc and Pd/C 10% (Pd) (4.0 g) was added. The mixture was hydrogenated at room temperature and normal pressure for 18 hours. The mixture was filtered over Kieselgur (Supelco) and evaporated. The residue was purified by flash chromatography on silica (EtOAc) to afford the compound Intermediate 5 as a beige solid.
WO 2013/008095 PCT/IB2012/001699 - 38 MS (ESI): 252 [M+H]* , 'H-NMR (DMSO-d 6 ): 6 (ppm) 6.52 (m, 2H), 5.11 (br s, 2NH), 2.19 (s, 3H), 1.29 (s, 12H). (6) 4-[4-(3-Amino-5-fluoro-2-methyl-phenyl)-7H-pyrrolo[2,3-d1 pyrimid in-6-yll-3,6 dihydro-2H-pyridine-1-carboxylic acid dimethylamide, Intermediate 6 F
NH
2 N N N N N H / To a mixture of chloro compound Intermediate 3 (3.94 g, 15.70 mmol) and dichlorobis(triphenylphosphine)palladium (II) (0.73 g, 1.04 mmol) in 1-propanol (150 ml) and aqueous sodium carbonate solution (2M, 6.54 ml, 13.08 mmol), boronic ester compound Intermediate 5 (4.0 g, 13.08 mmol) was added. The mixture was heated at 1000C for 16 hours. After cooling the brownish mixture was diluted with 200 ml water and extracted with EtOAc. The organic layer was washed with brine (2x) and dried over sodium sulfate, than filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc/methanol/ammonia 98:2:0.2 to EtOAc/MeOH/NH40H 9:1:0.1) to afford the compound Intermediate 6 as a beige solid. MS (ESI): 395 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 11.80 (br s, 1H), 8.87 (s, 1H), 6.70 (m, 1H), 6.55 (m, 1H), 6.48 (br s, 1H), 6.38 (br s, 1H), 4.05 (br s, 2H), 3.90 (br s, 2NH), 3.55 (m, 2H), 2.90 (s, 6H), 2.65 (m, 2H), 2.10 (s, 3H). (7) 4-(4-{5-Fluoro-3-[4-( -fluoro-cyclopropyl)-benzoylaminol-2-methyl-phenyll-7H pyrrolo[2'3-dpyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide H F F N O N 0 N N N H / WO 2013/008095 PCT/IB2012/001699 - 39 Anilino compound Intermediate 6 (80 mg, 0.203 mmol), 4-(1-fluoro-cyclopropyl)-benzoic acid (for preparation see WO 07/090752) (40 mg, 0.223 mmol) and COMU (130 mg, 0.304 mmol) were dissolved in DIPEA (0.071 ml, 0.406 mmol) and DMA (1.0 ml). The solution was stirred at room temperature for 18 hrs. The reaction was diluted with 10 ml EtOAc and extracted with water by a Hamilton extractor. The water layer was extracted with EtOAc (5x). The combined organic layers were dried with sodium sulfate and evaporated. The residue was purified by a preparative LC/MS method 1 to afford the compound Example 1 as a beige solid. MS (ESI): 557 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (br s, 1H), 10.07 (s, 1H), 8.83 (s, 1H), 8.03 (d, 2H), 7.49 (m, 1H), 7.43 (d, 2H), 7.23 (m, 1H), 6.59 (br s, 1H), 6.33 (s, 1H), 3.90 (m, 2H), 3.33 (m, 2H), 2.77 (s, 6H), 2.54 (m, 2H), 2.12 (s, 3H), 1.55 (m, 2H), 1.26 (m, 2H). The following Examples 2 - 14 were prepared as outlined in Reaction Scheme 1 and described for Example 1 using the intermediate Intermediate 6 and the appropriate benzoic acid as starting materials. Example 2 4-(4-{3-[(3,3-Dimethyl-2,3-d ihydro-benzofuran-6-carbonyl)-aminol-5-fluoro-2-methyl phenvll-7H-pvrrolo[2'3-dpvrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide H F N O N 0 N N N H / LC/MS (Method 1): rt: 1.01 minutes, MS (ESI): 569 [M+H]* WO 2013/008095 PCT/1B2012/001699 - 40 Example 3 4-(4-{5-Fluoro-2-methyl-3-[(5-methyl-4,5,6, 7-tetrahVdro-benzo[blthiophene-2-carbonvl) amino]-Dhenyll-7H-Ipyrrolo[2'3-d]Ijyrimid in-6-vI)-3,6-d ihvdro-2 H-Dyridine-lI-carboxylic acid dimethylamide H F N Y S - 0 N~ / KN NN N H/ LC/MS (Method I): rt: 1.14 minutes, MS (ESI): 573 [M+H]' Example 4 4-(4-{5-Fluoro-3-[4-isorrorvl-methvl-amino)-benzovlaminol-2-methl-Dhenvll-7H Dyvrrolo[2'3-d]Dyvrimid in-6-vI)-3. 6-d ihvd ro-2H-Dyvridi ne-I -carboxylic acid dimethylamide H I F N . N - 0 N N N H/ LCIMS (Method 1): rt: 1.05 minutes, MS (ESI): 570 [M+H]' WO 2013/008095 PCT/IB2012/001699 - 41 Example 5 3-Methyl-1 H-indole-6-carboxylic acid {3-[6-(1-dimethylcarbamoyl-1,2,3,6-tetrahydro pyridin-4-yl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll-5-fluoro-2-methyl-phenyll-amide H F N N YaH N 0 N N
N
H / LC/MS (Method 1): rt: 0.95 minutes, MS (ESI): 552 [M+H]* Example 6 4-(4-{5-Fluoro-3-[4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoylaminol-2-methyl-phenyll-7H pyrrolo[2,3-dipyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide H I F N OH 0 7N 0 N SN N H / LC/MS (Method 1): rt: 0.88 minutes, MS (ESI): 571 [M+H]* WO 2013/008095 PCT/1B2012/001699 - 42 Example 7 4-{4-[5-Fluoro-2-methvl-3-(4-piperid in-I -VI-benzoVlamino)-phenVl-7H-pwrrolo[2 .3 dl Dyrimid in-6-vll-3,6-dihvd ro-2 H-Dyvridime-li-carboxylic acid d imethylam ide ND H F N YCI N 0 KN N N H/ LC/MS (Method 1): rt: 1.07 minutes, MS (ESI): 582 [M+H]+ Example 8 4-{4-[5-Fluoro-3-(isoiroienyl-benzolamino)-2-methyl-Dhenyl-7H-Dyrrolo[2 .3 dl Dyrimid in-6-vll-3,6-dihvd ro-2 H-Dyvridime-li-carboxylic acid d imethylam ide H 11
-
F N YI N 0 C N H/ LCIMS (Method 1): rt: 1.04 minutes, MS (ESI): 539 [M+H]+ WO 2013/008095 PCT/1B2012/001699 - 43 Example 9 4-(4-{5-Fluoro-2-methyl-3-[4-(lI-trifluoromethVl-cVclopropwl)-benzovlamino]-phenl}-7H Dyvrrolo[2 .3-dli~vrimid in-6-vI)-3,6-dihvdro-2 H-Dyvridime-li-carboxylic acid d imethylamide H IF F F N 't F 07 0 9 N N_ H/ LC/MS (Method 1): rt: 1.08 minutes, MS (ESI): 607 [M+H]+ Example 10 4-{4-[5-Fluoro-3-(4-isopropoxv-benzovlamino)-2-methvI-phenI]-7H-pwrrolo[2 .3 dl Dyrimid in-6-vll-3,6-dihvd ro-2 H-Dyvridime-li-carboxylic acid d imethylam ide 0 H F N Y -.. N 0 N N N H/ LCIMS (Method 1): rt: 1.04 minutes, MS (ESI): 557 [M+H]+ WO 2013/008095 PCT/1B2012/001699 - 44 Example 11 4-(4-{5-Fluoro-3-[4-pentafluorothio-benzovlamino-2-methvl-henVl}-7H-pwrrolo[2 .3 dl Dyrimid in-6-vI)-3. 6-d ihvd ro-2 H-Dyvridine-lI-carboxylic acid dimethylamide F 'F S-F H F F F N -a N 0 N N N H/ LC/MS (Method 1): rt: 1.07 minutes, MS (ESI): 625 [M+H]+ Example 12 4-(4-{5-Fluoro-3-[4-(2-methoxv- 1.1-d imethyl-ethyl)-benzovlamino]-2-methyl-Dhenyll-7H Dyvrrolo[2 .3-di~yrimid in-6-vI)-3,6-dihvdro-2 H-Dyvridime-li-carboxylic acid d imethylamide HI F N 011 N 0 C NN H/ LCIMS (Method 1): rt: 1.04 minutes, MS (ESI): 585 [M+H]+ WO 2013/008095 PCT/1B2012/001699 - 45 Example 13 4-(4-{5-Fluoro-3-[4-(1 -methoxV-1I-methyl-ethyl)-benzovlamino]-2-methyl-rhenyl}-7H Dyvrrolo[2 .3-dl Dyrimidin-6-vI)-3,6-d ihvdro-2 H-Dyvridime-li-carboxylic acid d imethylamide 0 H I I F N *NC N NN4 H/ LC/MS (Method 1): rt: 0.98 minutes, MS (ESI): 571 [M+H]+ Example 14 1-Methyl-I H-Dyrrolo[2 .3-b] Dyrid ine-6-carboxylic acid {3-[6-(lI-dimethyl-carbamoyl-1 .2.3.6 tetrahyd ro-Dyvrid in-4-vI)-7 H-Dyvrrolo[2 .3-dli~yrimid in-4-vI]-5-fluoro-2-methyl-Dhenyll-amide H F N N N N 0 N N N H/ LCIMS (Method 1): rt: 0.85 minutes, MS (ESI): 553 [M+H]+ WO 2013/008095 PCT/IB2012/001699 - 46 Example 15 4-{4-[3-(4-DimethVlamino-benzovlamino)-5-fluoro-2-methyl-phenll-7H-pyrrolo[2,3 dl pyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide N N 0 HN F r-7 N4 N N N H / To a solution of aniline Intermediate 6 (84 mg, 0.213 mmol) in DCM/pyridine (2:1, 30 ml) were added DIPEA (0.372 ml, 2.13 mmol), 4-dimethylaminobenzoyl chloride (43 mg, 0.234 mmol), and DMAP (2.6 mg, 0.021 mmol). The resulting mixture was stirred at room temperature for 75 hrs. The solvents were removed in vacuo and the resulting mixture was purified by reversed phase HPLC (MeCN/H 2 0) to afford Example 15. MS (ESI): 542 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.41 (br s, 1H), 9.63 (s, 1H), 8.81 (s, 1H), 7.88 (d, 2H), 7.48 (m, 1H), 7.16 (m, 1H), 6.77 (d, 2H), 6.58 (br s, 1H), 6.32 (s, 1H), 3.89 (br s, 2H), 3.32 (m, 2H), 3.00 (s, 6H), 2.76 (s, 6H), 2.54 (m, 2H), 2.10 (s, 3H). Example 16 4-(4-{3-[2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylaminol-2-hydroxymethyl-phenyll 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide WO 2013/008095 PCT/IB2012/001699 - 47 OH 0 N NH F OH 0 N N ~ -N N N H (1) 4-{4-[3-Amino-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenyll-7H-pyrrolo[2,3 dlpyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide, Intermediate 7 .o Q~N 0 S N N N H /N Intermediate 7 was prepared analogue to Intermediate 6 by replacing the boronic ester Intermediate 5 with the boronic ester Intermediate 27. MS (ESI): 631 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.24 (br s, 1H), 8.52 (s, 1H), 7.32 (m, 2H), 7.28-7.27 (m, 4H), 716-7.15 (m, 5H), 6.90 (d, 1H), 6.71 (d, 1H), 6.53 (m, 1H), 6.16 (s, 1H), 5.28 (br s, 2H), 4.82 (s, 2H), 3.88 (m, 6H), 3.31 (m, 2H), 2.75 (s, 6H), 2.44 (m, 2H), 0.81 (s, 9H). (2) 2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoic acid, Intermediate 8 OH F HO,; 0 WO 2013/008095 PCT/IB2012/001699 - 48 Intermediate 8 was prepared analogue to Intermediate 35 by replacing Intermediate 34 with 2-fluoro-terephthalic acid 4-methyl ester (J. Med. Chem., 52(19), 5950-5966; 2009). MS (ESI): 197 [M-H]- , 'H-NMR (DMSO-d 6 ): 6 (ppm) 7.80 (t, 1H), 7.35 (m, 1H), 7.32 (m, 1H), 5.27 (br s, 1H), 1.42 (s, 6H). (3) 4-(4-{2-(tert-Butyl-diphenyl-silanyloxymethyl)-3-[2-fluoro-4-(1-hydroxy-1-methyl ethyl)-benzoylaminol-phenyll-7H-pyrrolo[2,3-di pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1 carboxylic acid dimethylamide, Intermediate 9 OH F 0 H N
K
jSi _ H / To a mixture of Intermediate 7 (58 mg, 0.091 mmol), Intermediate 8 (27 mg, 0.137 mmol), and DIPEA (0.059 ml, 0.337 mmol) in DMF (10 ml) was added HATU (38 mg, 0.100 mmol). The resulting mixture was stirred at r.t. for 22 hrs. The mixture was diluted with EtOAc and sat. NaHCO3 solution. The organic layer was washed with brine and dried over Na2SO 4 . The solvents were removed in vacuo, and the crude product was purified by reversed pahse HPLC (H 2 0/MeCN) to afford Intermediate 9. (4) 4-(4-{3-[2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylaminol-2-hydroxymethyl phenyl}-7H-pyrrolo[2,3-dj pyrimid in-6-yl)-3,6-d ihyd ro-2H-pyrid ine-1 -carboxylic acid dimethylamide WO 2013/008095 PCT/IB2012/001699 - 49 OH 0 N NH F OH N -N N N H Example 16 was prepared analogue to Example 37 step 8 by replacing Intermediate 31 with Intermediate 9. LC/MS (Method 1): rt: 1.94 minutes, MS (ESI): 573 [M+H]* Example 17 4-{4-[3-(4-Cyclopropyl-benzoylamino)-2-hydroxymethyl-phenyll-7H-pyrrolo[2,3 dl pyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide O NH OH N -N N N H Example 17 was prepared analogue to Example 16 by replacing Intermediate 8 in step 3 with 4-cyclopropylbenzoic acid. LC/MS (Method 1): rt: 2.32 minutes, MS (ESI): 537 [M+H]* WO 2013/008095 PCT/IB2012/001699 - 50 Example 18 4-(4-{5-Fluoro-2-methyl-3-[4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)-benzoylaminol phenyll-7H-pvrrolo[2,3-dl pyrimid in-6-yl)-3,6-d ihyd ro-2H-pyrid ine-1 -carboxylic acid dimethylamide HO F O F F F NH 0 N 0- , -N N N H Example 18 was prepared analogue to Intermediate 9 by replacing Intermediate 7 with Intermediate 6 and Intermediate 8 with 4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl) benzoic acid (W02007/145834). MS (ESI): 611 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (br s, 1H), 10.10 (s, 1H), 8.83 (s, 1H), 8.03 (d, 2H), 7.77 (d, 2H), 7.49 (m, 1H), 7.22 (m, 1H), 6.77 (s, 1H), 6.60 (br s, 1H), 6.34 (s, 1H), 3.90 (m, 2H), 3.35 (m, 2H), 2.77 (s, 6H), 2.55 (m, 2H), 2.10 (s, 3H), 1.75 (s, 3H). Example 19 4-{4-[3-(4-Acetyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H-pyrrolo[2,3-dlpyrimidin-6 yll-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O /~ 0 0 HN F N4 N N N H / WO 2013/008095 PCT/IB2012/001699 - 51 Example 19 was prepared analogue to Example 18 by replacing 4-(2,2,2-trifluoro-l hydroxy-1-methyl-ethyl)-benzoic acid with 4-acetyl-benzoic acid. MS (ESI): 541 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.42 (br s, 1H), 10.24 (s, 1H), 8.82 (s, 1H), 8.11 (m, 4H), 7.48 (m, 1H), 7.24 (m, 1H), 6.59 (s, 1H), 6.33 (s, 1H), 3.89 (m, 2H), 3.34 (m, 2H), 2.76 (s, 6H), 2.65 (s, 3H), 2.53 (m, 2H), 2.13 (s, 3H). Example 20 4-{4-[3-(4-Cyclopropyl-benzoylamino)-4-fluoro-phenyll-7H-pyrrolo[2,3-d]pyrimidin-6-ylL 3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide H F N 0N N N N H / (1) 4-[4-(3-Amino-4-fluoro-phenyl)-7H-pyrrolo[2,3-dlpvrimidin-6-vll-3,6-dihydro-2H pyridine-1-carboxylic acid dimethylamide, Intermediate 10 F
H
2 N IN N N N H / Intermediate 10 was prepared analogue to Intermediate 6 by replacing Intermediate 5 with 3-amino-4-fluoroboronic acid. MS (ESI): 381 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.32 (br s, 1H), 8.74 (s, 1H), 7.68 (m, 1H), 7.39 (m, 1H), 7.13 (m, 1H), 6.84 (s, 1H), 6.58 (s, 1H), 5.36 (br s, 2H), 3.91 (s, 2H), 3.37 (m, 2H), 2.77 (s, 6H), 2.62 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 52 (2) 4-{4-[3-(4-Cyclopropyl-benzoylamino)-4-fluoro-phenyll-7H-pyrrolo[2,3 dl pyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide H F N N4 N N N H / A mixture of Intermediate 10 (80mg, 0.210 mmol), 4-cyclopropyl-benzoyl chloride (J. Med. Chem., 52(14), 4329-4337; 2009) (76 mg, 0.421 mmol), and DMAP (2.6 mg, 0.021 mmol) in pyridine (2 ml) was stirred at r.t. overnight. The mixture was evaporated to dryness, then sat. aqueous NaHCO 3 was added, and the mixture was extracted with DCM. The organic layer was dried, filtered, and evaporated to dryness. The residue was purified by flash chromatography (silica gel, EtOAc/MeOH/NH 3 gradient) to obtain Example 20. MS (ESI): 525 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (br s, 1H), 10.20 (s, 1H), 8.80 (s, 1H), 8.47 (d, 1H), 8.09 (m, 1H), 7.92 (d, 2H), 7.49 (t, 1H), 7.25 (d, 1H), 6.93 (s, 1H), 6.60 (s, 1H), 3.91 (m, 2H), 3.35 (m, 2H), 2.77 (s, 6H), 2.62 (m, 2H), 2.02 (m, 1H), 1.04 (m, 2H), 0.78 (m, 2H). Example 21 4-(4-{4-Fluoro-3-[4-(2-hydroxy-1, 1-dimethyl-ethyl)-benzovlaminol-phenyll-7H-pvrrolo[2,3 dl pyrimidin-6-yl)-3, 6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide OH H F N N4 N N N H / WO 2013/008095 PCT/IB2012/001699 - 53 Example 21 was prepared analogue to Intermediate 9 by replacing Intermediate 7 with Intermediate 10 and Intermediate 8 with 4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoic acid. MS (ESI): 557 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.41 (br s, 1H), 10.21 (s, 1H), 8.80 (s, 1H), 8.50 (m, 1H), 8.10 (m, 1H), 7.94 (d, 2H), 7.54 (d, 2H), 7.48 (m, 1H), 6.93 (s, 1H), 6.60 (s, 1H), 4.74 (br s, 1H), 3.91 (m, 2H), 3.48 (m, 2H), 3.34 (m, 2H), 2.77 (s, 6H), 2.62 (m, 2H). 1.27 (s, 6H). Example 22 N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d1pyrimid in-4-yll-5-fluoro-2-methyl phenyll-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide OH 0 HN F N N H (1) 4-Chloro-6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dpyrimidine, Intermediate 11 CI H Intermediate 11 was prepared analogue to Intermediate 1 by replacing 4-(4,4,5,5 tetramethyl-[1,2,3]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester with 3,6-dihydro-2H-pyran-4-boronic acid pinacolester. MS (ESI): 236 [M+H]* , 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.69 (brs, 1H), 8.56 (s, 1H), 6.67 (m, 1H), 6.58 (s, 1H), 4.29 (m, 2H), 3.84 (m, 2H), 2.50 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 54 (2) 3-[6-(3,6-Dihyd ro-2 H-pyran-4-yl)-7H-pyrrolo[2,3-d1pyrimid in-4-yl1-5-fluoro-2 methyl-phenylamine, Intermediate 12 F NH 2 NO N N H Intermediate 12 was prepared analogue to Intermediate 6 by replacing Intermediate 3 with Intermediate 11. MS (ESI): 325 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.34 (br s, 1H), 8.77 (s, 1H), 6.62 (m, 1H), 6.56 (m, 1H), 6.37 (m, 1H), 6.25 (s, 1H), 5.37 (br s, 2H), 4.27 (m, 2H), 3.80 (m, 2H), 2.45 (m, 2H), 1.89 (s, 3H). (3) N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dl pyrimid in-4-yll-5-fluoro-2 methyl-phenyll-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide OH 0 HN F H Example 22 was prepared analogue to Intermediate 9 by replacing Intermediate 7 with Intermediate 12. MS (ESI): 505 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.45 (br s, 1H), 9.95 (s, 1H), 8.83 (s, 1H), 7.73 (m, 1H), 7.63 (m, 1H), 4.43 (m, 2H), 7.19 (m, 1H), 6.65 (s, 1H), 6.34 (s, 1H), 5.32 (s, 1H), 4.29 (s, 2H), 3.81 (m, 2H), 2.47 (m, 2H), 2.15 (s, 3H), 1.46 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 55 Example 23 N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dlpvrimidin-4-yll-2-hydroxymethyl phenyll-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide HO 0 F HN HO NO N N / KH (1) 2-(tert-Butyl-diphenyl-silanyloxymethyl)-3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yll-phenylamine, Intermediate 13 .0 ~ HH Intermediate 13 was prepared analogue to Intermediate 7 by replacing Intermediate 6 with Intermediate 11. MS (ESI): 561 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.25 (br s, 1H), 8.52 (s, 1H), 7.40 7.10 (m, 11H), 6.90 (d, 1H), 6.71 (d, 1H), 6.59 (s, 1H), 6.16 (s, 1H), 5.28 (s, 2H), 4.81 (s, 2H), 4.27 (m, 2H), 3.78 (m, 2H), 2.37 (m, 2H), 0.82 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 56 (2) N-{2-(tert-Butyl-d iphenyl-silanyloxymethyl)-3-[6-(3,6-d ihyd ro-2 H-pyran-4-yl)-7H pyrrolo[2,3-dl pyrimidin-4-yll-phenyll-2-fluoro-4-(1 -hydroxy-1 -methyl-ethyl)-benzamide, Intermediate 14 HO F HN N Si N /O IN N0 H Intermediate 14 was prepared analogue to Intermediate 9 by replacing Intermediate 7 with Intermediate 13. (3) N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dl pyrimidin-4-yll-2 hydroxymethyl-phenyll-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide HO F HN HO N N / 'N N Example 23 was prepared analogue to Example 16 step 4 by replacing Intermediate 9 with Intermediate 14. MS (ESI): 503 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.42 (s, 1H), 10.39 (d, 1H), 8.82 (s, 1H), 8.19 (d, 1H), 7.86 (t, 1H), 7.52-7.30 (m, 4H), 6.62 (br s, 1H), 6.42 (s, 1H), 5.65 (m, 1H), 5.26 (s, 1H), 4.63 (m, 2H), 4.27 (m, 2H), 3.80 (m, 2H), 2.41 (m, 2H), 1.45 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 57 Example 24 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-dlpVrimidin-4-yll-5 fluoro-2-methyl-phenyll-benzamide H F N N 1 0 N N H (1) 4-Chloro-6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidine, Intermediate 15 CI N -N H Intermediate 15 was prepared analogue to Intermediate 1 by replacing 4-(4,4,5,5 tetramethyl-[1,2,3]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester with 2-(3,6-d ihyd ro-2 H-thiopyran-4-yl)-4,4,5,5-tetramethyl-[1,3,2]d ioxaborolane. MS (ESI): 252 [M+H]* (2) 3-[6-(3,6-Dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-di pyrimidin-4-yll-5-fluoro-2 methyl-phenylamine, Intermediate 16 F
INH
2 N S N H WO 2013/008095 PCT/IB2012/001699 - 58 Intermediate 16 was prepared analogue to Intermediate 6 by replacing Intermediate 3 with Intermediate 15. MS (ESI): 341 [M+H]* (3) 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4yl)-7H-pyrrolo[2,3-dlpyrimidin-4 vll-5-fluor-2-methyl-phenyll-benzamide H F N N N N H Example 24 was prepared analogue to Example 15 by replacing Intermediate 6 with Intermediate 16 and 4-dimethyaminobenzoyl chloride with tert-butylbenzoyl chloride. MS (ESI): 501 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.39 (s, 1H), 9.97 (s, 1H), 8.82 (s, 1H), 7.95 (d, 2H), 7.56 (d, 2H), 7.47 (m, 1H), 71.19 (m, 1H), 6.78 (m, 1H), 6.34 (s, 1H), 3.37 (m, 2H), 2.82 (m, 2H), 2.66 (m, 2H), 2.11 (s, 3H), 1.32 (s, 9H). Example 25 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-7H pyrrolo[2,3-dl pyrimidin-4-yll-phenyl-benzamide H F N 7N 0 S=0 N N H Example 24 (160 mg, 0.32 mmol) was dissolved in acetic acid (5 ml) and hydrogen peroxide (0.033 ml, 0.32 mmol) was added. The mixture was stirred at room temperature WO 2013/008095 PCT/IB2012/001699 - 59 for 2 hours. The mixture was treated with sodium hydrogen sulfite solution (10%, 10 ml) for 10 minutes, diluted with water, basified with 2N sodium hydroxide solution and extracted with EtOAc. The organic layer was washed with brine (2x), dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc/MeOH/NH 4 0H 9:1:0.1 to EtOAc/MeOH/NH 4 0H 85:15:1.5) to afford the compound Example 25 as a beige solid. MS (ESI): 517 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.49 (br s, 1H), 9.99 (s, 1H), 8.85 (s, 1H), 7.96 (d, 2H), 7.55 (d, 2H), 7.49 (m, 1H), 7.21 (m, 1H), 6.49 (br s, 1H), 6.46 (s, 1H), 3.69 (m, 1H), 3.50 (m, 1H), 3.13 (m, 1H), 295 (m, 1H), 2.89 (m, 1H), 2.80 (m, 1H), 2.13 (s, 3H), 1.31 (s, 9H). Example 26 4-tert-Butyl-N-{3-[6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-5-fluoro-2-methyl-phenyll-benzamide H | F N - 0 0
O
N N H Example 24 (160 mg, 0.32 mmol) was dissolved in DCM (15 ml), then trifluoro acetic acid (5 ml) and hydrogen peroxide (0.065 ml, 0.64 mmol) were added. The mixture was stirred at room temperature for 2 hours. The mixture was treated with sodium hydrogen sulfite solution (10%, 10 ml) for 10 minutes, diluted with water, basified with 2N sodium hydroxide solution and extracted with EtOAc. The organic layer was washed with brine (2x), dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc/MeOH/NH 4 0H 98:2:0.2 to EtOAc/MeOH/NH 4 0H 95:5:0.5) to afford the compound Example 26 as a beige solid. MS (ESI): 533 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.45 (br s, 1H), 9.93 (s, 1H), 8.84 (s, 1H), 7.91 (d, 2H), 7.56 (d, 2H), 7.49 (m, 1H), 7.21 (m, 1H), 6.41 (m, 2H), 4.00 (m, 2H), 3.36 (m, 2H), 3.07 (m, 2H), 2.16 (s, 3H), 1.33 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 60 Example 27 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.51dec-7-en-8-l)-7H-pyrrolo[2,3-d]pyrimidin-4-yll-5 fluoro-2-methyl-phenyll-benzamide - 0 HN F Intermediate 17 CI r;K / H Intermediate 17 was prepared analogue to Intermediate 1 by replacing 4-(4,4,5,5 tetramethyl-[1 ,2 ,3]d ioxaborolan-2-yl)-3,6-d ihydro-2H-pyridine-1i-carboxylic acid tert-butyl ester with 1 ,4-dioxaspiro[5,5]dec-7-en-8-boronic acid pinacol ester. MS (ESI): 292 [M+H]* , H-NMR (DMSO-d 6 ): 6 (ppm) 12.59 (br s, 1H), 8.54 (s, 1H), 6.54 (s, 1H), 6.50 (br s, 1H), 3.93 (in, 4H), 2.61 (in, 2H), 2.43 (in, 2H), 1.83 (mn, 2H). (2) 3-[6-(1,.4-Dioxa-spiro[4.51dec-7-en-8-yl)-7H-pyrrolo[2,3-dipyrimidin-4-yll-5-fluoro 2-methyl-phenylamine, Intermediate 18
H
2 N F O
H
WO 2013/008095 PCT/IB2012/001699 - 61 Intermediate 18 was prepared analogue to Intermediate 6 by replacing Intermediate 3 with Intermediate 17. MS (ESI): 381 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.24 (br s, 1H), 8.75 (s, 1H), 6.55 (m, 1H), 6.46 (br s, 1H), 6.38 (m, 1H), 6.21 (s, 1H), 5.36 (s, 2 NH), 3.91 (m, 4H), 2.55 (m, 2H), 2.41 (m, 2H), 1.88 (s, 3H), 1.78 (m, 2H). (3) 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.51dec-7-en-8-yl)-7H-pyrrolo[2,3-dipyrimidin 4-vll-5-fluoro-2-methyl-phenyl}-benzam ide - 0 HN F I/ N N O H Example 27 was prepared analogue to Example 15 by replacing Intermediate 6 with Intermediate 18 and 4-dimethyaminobenzoyl chloride with 4-tert-butylbenzoyl chloride. MS (ESI): 541 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.36 (br s, 1H), 9.98 (s, 1H), 8.82 (s, 1H), 7.96 (d, 2H), 7.58 (d, 2H), 7.48 (m, 1H), 7.21 (m, 1H), 6.50 (br s, 1H), 6.29 (s, 1H), 3.93 (m, 4H), 2.58 (m, 2H), 2.43 (m, 2H), 2.12 (s, 3H), 1.81 (m, 2H), 1.33 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 62 Example 28 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll 2-methyl-phenyll-benzamide - 0 HN F OH N N H (1) 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hydroxy-cyclohex- 1 -enyl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-2-methyl-phenyll-benzamide, Intermediate 19 - 0 HN F N N N H A mixture of Example 27 (450 mg, 0.832 mmol) and TFA (6 ml) in DCM (30ml) was stirred at r.t. for 6 hrs. The solvents were removed in vacuo and the crude product was purified by flash chromatography (silica gel, EtOAc/MeOH/NH 4 0H gradient) to yield Intermediate 19. MS (ESI): 497 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.47 (br s, 1H), 9.97 (s, 1H), 8.83 (s, 1H), 7.94 (d, 2H), 7.57 (d, 2H), 7.48 (m, 1H), 7.20 (m, 1H), 6.65 (br s, 1H), 6.40 (s, 1H), 3.11 (m, 2H), 2.86 (m, 2H), 2.53 (m, 2H), 2.11 (s, 3H), 1.33 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 63 (2) 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hydroxy-cyclohex-1 -enyl)-7H-pyrrolo[2,3 dl pyrim id in-4-vll-2-methyl-phenyll-benzamide 0 HN F OH N N H To a solution of Intermediate 19 (100 mg, 0.201 mmol) in MeOH (25 ml) was added NaBH 4 (9.1 mg, 0.242 mg). The mixture was stirred at r.t. for 2 hrs, then the solvent was removed in vacuo, and the crude mixture was purified by flash chromatography (silica gel, EtOAc/MeOH/NH 4 0H gradient) to yield Example 28. MS (ESI): 499 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.31 (br s, 1H), 9.96 (s, 1H), 8.79 (s, 1H), 7.94 (d, 2H), 7.57 (d, 2H), 7.47 (m, 1H), 7.18 (m, 1H), 6.50 (br s, 1H), 6.24 (s, 1H), 4.73 (br s, 1H), 3.80 (m, 1H), 2.51 (m, 2H), 2.44 (m, 1H), 2.39 (m, 1H), 2.10 (s, 3H), 1.84 (m, 1H), 1.59 (m, 1H), 1.33 (s, 9H). Example 29 4-{4-[3-(4-Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H-pyrrolo[2'3 dl pyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide H | F N N 0 N N N H / WO 2013/008095 PCT/IB2012/001699 - 64 (1) 4-[4-(3-Amino-5-fluoro-2-methyl-phenyl)-7H-pyrrolo[2,3-d] pyrimid in-6-yll-3,6 dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester, Intermediate 20 F
NH
2 N 0/ N N 0 H For the Suzuki coupling of chloro compound Intermediate 1 (0.63 g, 1.88 mmol) and boronic ester derivative Intermediate 5 (0.52 g, 2.07 mmol) the same procedure was used as described in Example 1 step 6, to afford the compound Intermediate 20 as a beige solid. MS (ESI): 424 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.33 (br s, 1H), 8.76 (s, 1H), 6.54 (m, 2H), 6.40 (d, 1H), 6.26 (s, 1H), 5.36 (s, 2NH), 4.05 (br s, 2H), 3.51 (m, 2H), 1.99 (m, 2H), 1.88 (s, 3H), 1.42 (s, 9H). (2) 4-{4-[3-(Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H-pyrrolo[2,3 dlpyrimidin-6-yll-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester, Intermediate 21 H F N 0 N N N 0 H To a solution of 4-cyclopropyl benzoic acid (0.58 g, 3.57 mmol) in toluene (2 ml), thionyl chloride (1.29 ml, 17.87 mmol) was added. The mixture was stirred at 800C for 2 hours and afterwards evaporated under reduced pressure. The residue was dissolved together with Intermediate 20 (1.0 g, 2.36 mmol) in pyridine (5 ml) and the mixture was stirred at room temperature for 2 hours. Pyridine was evaporated under reduced pressure and the WO 2013/008095 PCT/IB2012/001699 - 65 residue was dissolved in DCM and washed with saturated sodium hydrogen carbonate solution and brine (2x). The residue was purified by flash chromatography on silica (cyclohexane to EtOAc) to afford the compound Intermediate 21 as a beige solid. MS (ESI): 568 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (br s, 1H), 9.93 (s, 1NH) 8.82 (s, 1H), 7.89 (d, 2H), 7.46 (m, 1H), 7.24 (d, 2H), 7.18 (m, 1H), 6.57 (br s, 1H), 6.33 (s, 1H), 4.06 (br s, 2H), 3.52 (m, 2H), 2.48 (m, 2H), 2.10 (s, 3H), 2.01 (m, 1H), 1.42 (s, 9H), 1.02 (m, 2H), 0.76 (m, 2H). (3) 4-Cyclopropyl-N-{5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-dlpyrimidin-4-vll-phenyl}-benzamide, Intermediate 22 H F N - 0 N~ / NH N N H The BOC protecting group of compound Intermediate 21 (1.0 g, 1.76 mmol) was removed as described in Example 1 step 2 to afford the compound Intermediate 22 as a beige solid. MS (ESI): 468 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.33 (br s, 1H), 9.94 (s, 1NH) 8.80 (s, 1H), 7.89 (d, 2H), 7.47 (m, 1H), 7.24 (d, 2H), 7.19 (m, 1H), 6.62 (br s, 1H), 6.24 (s, 1H), 3.41 (br s, 2H), 2.88 (m, 2H), 2.33 (m, 2H), 2.10 (s, 3H), 2.01 (m, 1H), 1.04 (m, 2H), 0.77 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 66 (4) 4-{4-[3-(4-Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H-pyrrolo[2'3 dl pyrimidin-6-vl}-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide H | F N N 0 N N N H / The amino compound Intermediate 22 (0.2 g, 0.51 mmol) was acylated as described in Example 1 step 3 to afford the compound Example 29 as a beige solid. MS (ESI): 539 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.42 (br s, 1H), 9.93 (s, 1NH) 8.82 (s, 1H), 7.89 (d, 2H), 7.46 (m, 1H), 7.24 (d, 2H), 7.18 (m, 1H), 6.59 (br s, 1H), 6.32 (s, 1H), 3.90 (br s, 2H), 3.33 (m, 2H), 2.76 (s, 6H), 2.53 (m, 2H), 2.10 (s, 3H), 2.02 (m, 1H), 1.03 (m, 2H), 0.77 (m, 2H). Example 30 4-Cyclopropyl-N-(5-fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro pyridin-4-yll-7H-pyrrolo[2,3-d]pyrimidin-4-yl-phenyl)-benzamide H F N O N 0 N N H The amino compound Intermediate 22 (0.2 g, 0.51 mmol) was acylated using pyrrolidine-1-carbonyl chloride as described in Example 1 step 3 to afford the compound Example 30 as a beige solid.
WO 2013/008095 PCT/IB2012/001699 - 67 MS (ESI): 565 [M+H]* , 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.41 (br s, 1H), 9.93 (s, 1NH) 8.82 (s, 1H), 7.89 (d, 2H), 7.45 (m, 1H), 7.24 (d, 2H), 7.18 (m, 1H), 6.58 (br s, 1H), 6.32 (s, 1H), 3.93 (br s, 2H), 3.38 (m, 2H), 3.29 (m, 4H), 2.52 (m, 2H), 2.10 (s, 3H), 2.0 (m, 1H), 1.75 (m, 4H), 1.04 (m, 2H), 0.76 (m, 2H). Example 31 Acetic acid 2-(4-{4-[3-(4-cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H pyrrolo[2,3-dlpvrimidin-6-vl}-3,6-dihydro-2H-pyridin-1-yl)-2-oxo-ethy ester H F N 0 N NN H 0 The amino compound Intermediate 22 (0.15 g, 0.32 mmol) was acylated using acetic acid chlorocarbonylmethyl ester as described in Example 1 step 3 to afford the compound Example 31 as a beige solid. MS (ESI): 568 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.45 (br s, 1H), 9.94 (s, 1NH) 8.83 (s, 1H), 7.89 (d, 2H), 7.47 (m, 1H), 7.22 (d, 2H), 7.19 (m, 1H), 6.58 (br s, 1H), 6.34 (s, 1H), 4.86 (m, 2H), 4.15 (m, 2H), 3.57 (m, 2H), 2.59 (m, 2H), 2.10 (s, 3H), 2.08 (s, 3H), 2.01 (m, 1H), 1.03 (m, 2H), 0.77 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 68 Example 32 4-CVclopropI-N-(5-fluoro-3-{6-[1-(2-hydroxy-actyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H pyrrolo[2,3-dl pyrimidin-4-vl}-2-methyl-phenyl)benzam ide H F N 7N 0 N N OH H O The acetyl compound of Example 31 (100 mg, 0.17 mmol) was dissolved in THF (1 ml) and EtOH (1 ml) and 2N sodium hydroxide solution (0.31 ml, 0.62 mmol) was added. The mixture was stirred at room temperature for 5 minutes. The mixture was diluted with water and extracted with DCM (3x). The organic layer was washed with brine (2x), dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc to EtOAc/MeOH/NH 4 0H 98:2:0.2) to afford the compound Example 32 as a beige solid. MS (ESI): 526 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.47 (br s, 1H), 9.95 (s, 1NH) 8.82 (s, 1H), 7.89 (d, 2H), 7.47 (m, 1H), 7.24 (d, 2H), 7.18 (m, 1H), 6.61 (m, 1H), 6.33 (m, 1H), 4.63 (m, 2H), 4.04 (m, 4H), 3.68 (m, 1H), 3.54 (m, 1H), 2.57 (m, 2H), 2.10 (s, 3H), 2.01 (m, 1H), 1.04 (m, 2H), 0.77 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 69 Example 33 N-(3-{6-[1-(2-Cyano-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H-pyrrolo[2,3-dpyrimidin-4 vll-5-fluoro-2-methyl-phenyl)-4-cyclopropvl-benzamide H | F N 7N 0 N N N H Amino compound Intermediate 22 (30 mg, 0.064 mmol), cyanoacetic acid (11 mg, 0.128 mmol) and HATU (61 mg, 0.16 mmol) were dissolved in DIPEA (0.056 ml, 0.321 mmol) and DMF (1.0 ml). The solution was stirred at room temperature for 24 hrs. The reaction was diluted with DCM and washed with saturated sodium hydrogen carbonate solution and brine (2x). The organic layer was dried with sodium sulfate and evaporated. The residue was purified by flash chromatography on silica (cyclohexane to EtOAc) to afford the compound Example 33 as a beige solid. MS (ESI): 536 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.56 (br s, 1NH) 8.76 (s, 1H), 7.85 (d, 2H), 7.43 (m, 1H), 7.19 (d, 2H), 7.09 (m, 1H), 6.53 (m, 1H), 6.29 (m, 1H), 4.16 (m, 2H), 3.94 (m, 2H), 3.63 (m, 2H), 2.56 (m, 2H), 2.10 (s, 3H), 2.01 (m, 1H), 1.01 (m, 2H), 0.74 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 70 Example 34 N-(5-Fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H pyrrolo[2,3-di pvrimidin-4-vll-phenyl)-4-(pentafluoro-sulfanyl)-benzamide F F -F FO HN F N N N N N 0 H (1) 4-(4-{5-Fluoro-2-methyl-3-[4-(pentafluoro-sulfanyl)-benzovlaminol-phenyl}-7H pyrrolo[2,3-dlpyrimidin-6-vl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester, Intermediate 23 F F H F F F N Y(: N 0 N4 N N 0 H Intermediate 23 was prepared analogue to Intermediate 9 by replacing Intermediate 7 with Intermediate 20 and Intermediate 8 with 4-(pentafluoro-sulfanyl)-benzoic acid. MS (ESI): 654 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (br s, 1H), 10.33 (s, 1H), 8.83 (s, 1H), 8.18 (d, 2H), 8.12 (d, 2H), 7.50 (m, 1H), 7.24 (m, 1H), 6.57 (m, 1H), 6.34 (s, 1H), 4.06 (m, 2H), 3.51 (m, 2H), 2.49 (m, 2H), 2.12 (s, 3H), 1.42 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 71 (2) N-{5-Fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-yll-phenyll-4-(pentafluoro-sulfanyl)-benzamide, Intermediate 24 F F,. IF FIS F'F O HN F 7N /NH N N Intermediate 24 was prepared analogue to Intermediate 22 by replacing Intermediate 21 with Intermediate 23. MS (ESI): 554 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.42 (br s, 1H), 10.43 (s, 1H), 8.83 (s, 1H), 8.23 (d, 2H), 8.13 (d, 2H), 7.51 (m, 1H), 7.24 (m, 1H), 6.54 (m, 1H), 6.31 (s, 1H), 3.52 (m, 2H), 2.99 (m, 2H), 2.45 (m, 2H), 2.13 (s, 3H). (3) N-(5-Fluoro-2-methyl-3-{6-[1 -(pyrrolid ine- 1 -carbonyl)- 1, 2,3,6-tetrahyd ro-pyrid in-4 yll-7H-pyrrolo[2,3-d1pyrimid in-4-yl}-phenyl)-4-(pentafluoro-sulfanyl)-benzamide F F,.. F FFl HN F N ri N N O Example 34 was prepared analogue to Example 30 by replacing Intermediate 22 with Intermediate 24. MS (ESI): 651 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.42 (br s, 1H), 10.32 (s, 1H), 8.82 (s, 1H), 8.18 (d, 2H), 8.12 (d, 2H), 7.48 (m, 1H), 7.23 (m, 1H), 6.59 (m, 1H), 6.33 (s, 1H), 3.93 (m, 2H), 3.38 (m, 2H), 3.29 (m, 4H), 2.50 (m, 2H), 2.12 (s, 3H), 1.75 (m, 4H).
WO 2013/008095 PCT/IB2012/001699 - 72 Example 35 Acetic acid 2-[4-(4-{5-fluoro-2-methyl-3-[4-(pentafluoro-sulfanVl)-benzoVlaminol-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridin-1-yll-2-oxo-ethyl ester F F... F I F O F F NH N N 0 N N N H 0 Example 35 was prepared analogue to Example 31 by replacing Intermediate 22 with Intermediate 24. MS (ESI): 654 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.47 (br s, 1H), 10.34 (s, 1H), 8.83 (s, 1H), 8.19 (d, 2H), 8.12 (d, 2H), 7.49 (m, 1H), 7.25 (m, 1H), 6.60 (m, 1H), 6.37 (s, 1H), 4.86 (s, 2H), 4.16 (m, 2H), 3.58 (m, 2H), 2.60 (m, 2H), 2.12 (s, 3H), 2.08 (s, 3H). Example 36 N-(5-Fluoro-3-{6-[1-(2-hydroxy-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H-pyrrolo[2,3 dl pyrimidin-4-yll-2-methyl-phenyl)-4-(pentafluoro-sulfanyl)-benzamide F F O F F NH NN HO N N
H
WO 2013/008095 PCT/IB2012/001699 - 73 Example 36 was prepared analogue to Example 32 by replacing Example 31 with Example 35. MS (ESI): 612 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (br s, 1H), 10.47 (s, 1H), 8.84 (s, 1H), 8.22 (d, 2H), 8.12 (d, 2H), 7.50 (m, 1H), 7.24 (m, 1H), 6.60 (m, 1H), 6.35 (s, 1H), 4.86 (s, 2H), 4.20 (m, 2H), 4.16 (m, 2H), 3.51 (m, 2H), 2.58 (m, 2H), 2.13 (s, 3H), 2.08 (s, 3H). Example 37 4-{4-[3-(4-tert-Butyl-benzoylamino)-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenyll-7H pyrrolo[2,3-di pvrimidin-6-vll-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 0 HN HO N 0/
K-
N N N H / (1) (2-Bromo-nitro-benzyloxy)-tert-butyl-diphenyl-silane, Intermediate 25 00 Br 0 Si N I To a solution of (2-bromo-6-nitro-phenyl)-methanol (10.0 g, 43.1 mmol) and imidazole (5.87 g, 86.0 mmol) in DMF (20 ml), tert-butyl-chloro-diphenyl-silane was added dropwise at room temperature. The mixture was stirred at 500C for 1 hour. The mixture WO 2013/008095 PCT/IB2012/001699 - 74 was diluted with EtOAc and washed with brine (2x). The organic layer was dried with sodium sulfate and evaporated. The residue was taken up in heptane and stirred at room temperature for 3 hours. The solid was filtered off to afford compound Intermediate 25 as a beige solid. MS (ESI): 471 [M+H]* , 1 H-NMR (CDCl3): 6 (ppm) 7.80 (m, 6H), 7.40 (m, 6H), 7.24 (m, 1H), 5.10 (s, 2H), 0.99 (s, 9H). (2) 2-[2-(tert-Butyl-d iphenyl-silanyloxymethyl)-3-nitro-phenyll-4,4,5,5-tetramethyl [1,3,21dioxaborolane, Intermediate 26 X / 'Si O--B 0 N I To a mixture of Intermediate 25 (5.0 g, 10.63 mmol) and bis(diphenylphosphino)ferrocenedichloropalladium (II) (0.43 g, 0.52 mmol) in 60 ml dioxane, bis-(pinacolato)-diboron (5.4 g, 21.26 mmol) and potassium acetate (6.25 g, 63.7 mmol) were added. The mixture was heated to 900C for 4 hours. After cooling the brownish mixture was filtered over Kieselgur (Supelco) and evaporated. The residue was purified by flash chromatography on silica (heptane to heptane/EtOAc 4:1) to afford the compound Intermediate 26 as a yellow oil. MS (ESI): no peaks, 1 H-NMR (CDCl3): 6 (ppm) 7.65 (m, 5H), 7.30 (m, 8H), 5.30 (s, 2H), 1.10 (s, 12H), 0.97 (s, 9H). (3) 2-(tert-Butyl-d iphenyl-silanyloxymethyl)-3-(4,4,5,5-tetramethyl-[1, 3,21d ioxborolan 2-yl)-phenylamine, Intermediate 27 ISi O-B 0 NH 2 WO 2013/008095 PCT/IB2012/001699 - 75 The nitro compound Intermediate 26 (10.0 g, 19.32 mmol) was dissolved in 300 ml EtOAc and Pd/C 10% (Pd) (2.0 g) were added. The mixture was hydrogenated at room temperature and normal pressure for 20 hours. The mixture was filtered over Kieselgur (Supelco) and evaporated. The residue was purified by flash chromatography on silica (cyclohexane to cyclohexane/EtOAc 4:1) to afford the compound Intermediate 27 as a yellow oil. MS (ESI): 488 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 7.63 (m, 4H), 7.44 (m, 2H), 7.39 (m, 4H), 7.03 (t, 1H), 6.91 (d, 1H), 6.84 (d, 1H), 5.10 (s, 2H), 5.08 (s, 2H), 0.99 (s, 12H), 0.98 (s, 9H). (4) 4-tert-Butyl-N-[2-tert-butyl-d iphenyl-silanyloxymethyl)-3-(4,4,5,5-tetramethyl [1,3,21dioxaborolan-2-yl)-phenyl1-benzamide, Intermediate 28 / ISi O--B 0 NH 0 The anilino compound Intermediate 27 (92.0 g, 189 mmol) was dissolved in DCM (1.2 I) and triethylamine (80 ml). To the mixture 4-tert-butylbenzoylchloride was added over 5 minutes at 00C. The mixture was stirred at room temperature for 1 hour. The mixture was washed with saturated ammonium chloride solution and brine (2x) and evaporated. The residue was taken up in hexane and stirred at room temperature for 3 hours. The solid was filtered off to afford compound Intermediate 28 as a beige solid. MS (ESI): 648 [M+H]* , 1 H-NMR (CDCl3): 6 (ppm) 9.85 (br s, 1H), 7.80 (m, 2H), 7.60 (m, 6H), 7.35-7.25 (m, 9H), 5.30 (s, 2H), 1.35 (s, 9H), 1.05 (s, 18H).
WO 2013/008095 PCT/IB2012/001699 - 76 (5) 4-{4-[3-(4-tert-Butyl-benzoylamino)-2-(tert-butyl-diphenyl-silanyloxymethyl) phenyll-7H-pyrrolo[2,3-dlpyrimid-6-vl}-3,6-dihvdro-2H-pyridin3-1 -carboxylic acid tert butyl ester, Intermediate 29 0 HN OSi. NN N N 0 H For the Suzuki coupling between chloro compound Intermediate 1 (0.50 g, 1.49 mmol) and boronic ester derivative Intermediate 28 (1.45 g, 2.24 mmol) the same procedure was used as described in Example 1 step 6, to afford the compound Intermediate 29 as a beige solid. MS (ESI): 820 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.33 (s, 1H), 10.02 (s, 1H), 8.68 (s, 1H), 7.78 (m, 2H), 7.75 (m, 1H), 7.46 (m, 2H), 7.40 (m, 1H), 7.25 (m, 2H), 7.12 (m, 1H), 7.11 (m, 8H), 6.54 (br s, 1H), 6.30 (s, 1H), 4.97 (s, 2H), 4.07 (m, 2H), 3.52 (m, 2H), 2.43 (m, 2H), 1.41 (s, 9H), 1.30 (s, 9H), 0.53 (s, 9H). (6) 4-tert-Butyl-N-{2-(tert-butyl-diphenyl-silanyloxymethyl)-3-[6-(1,2,3,6-tetrahydro pyridin-4-yl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll-benzamide, Intermediate 30 0 HN SiO N N/ NH b N N
H
WO 2013/008095 PCT/IB2012/001699 - 77 The BOC protecting group of compound Intermediate 29 (0.92 g, 1.12 mmol) was removed as described in Example 1 step 2 to afford the compound Intermediate 30 as a beige solid. MS (ESI): 720 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.50 (s, 1H), 10.08 (s, 1H), 8.72 (s, 1H), 7.80 (m, 2H), 7.75 (m, 1H), 7.53 (m, 1H), 7.42 (m, 1H), 7.26 (m, 2H), 7.15 (m, 2H), 7.11 (m, 8H), 6.56 (br s, 1H), 6.42 (s, 1H), 4.99 (s, 2H), 3.85 (m, 2H), 3.32 (m, 2H), 2.67 (m, 2H), 1.29 (s, 9H), 0.52 (s, 9H). (7) 4-{4-[3-(4-tert-Butyl-benzovlamino)-2-(tert-butyl-diphenyl-silanyloxymethyl) phenyll-7H-pyrrolo[2,3-dlpyrimidin-6-vl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, Intermediate 31 0 HN Si o N N N N H/ The amino compound Intermediate 30 (0.1 g, 0.14 mmol) was acylated as described in Example 1 step 3 to afford the compound Intermediate 31 as a beige solid. MS (ESI): 791 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.35 (s, 1H), 10.04 (s, 1H), 8.70 (s, 1H), 7.79 (m, 2H), 7.74 (m, 1H), 7.53 (m, 1H), 7.47 (m, 2H), 7.43 (m, 1H), 7.27 (m, 2H), 7.14-7.11 (m, 8H), 6.57 (br s, 1H), 6.30 (s, 1H), 4.98 (s, 2H), 3.91 (m, 2H), 3.32 (m, 2H), 2.76 (s, 6H), 2.52 (m, 2H), 1.31 (s, 9H), 0.53 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 78 (8) 4-{4-[3-(4-tert-Butyl-benzoylamino)-2-hyd roxymethyl-phenyll-7H-pyrrolo[2,3 dl pyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide 0 HN HO N4 N N N H / The compound Intermediate 31 (65 mg, 0.082 mmol) was dissolved in a 1M solution of tetrabutyl ammonium fluoride in THF (2 ml, 2.0 mmol). The mixture was stirred at room temperature for 20 hours. The solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica (EtOAc/MeOH/NH 4 0H 95:5:0.5) to afford the compound Example 37 as a beige solid. MS (ESI): 553 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (s, 1H), 10.53 (s, 1NH) 8.83 (s, 1H), 8.23 (m, 1H), 7.91 (d, 2H), 7.60 (d, 2H), 7.51 (m, 1H), 7.35 (m, 1H), 6.60 (br s, 1H), 6.45 (s, 1H), 4.69 (s, 2H), 3.90 (br s, 2H), 3.33 (m, 2H), 2.77 (s, 6H), 2.54 (m, 2H), 1.33 (s, 9H). Example 38 4-tert-Butyl-N-(3-{6-[1-(2-fluoro-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H-pyrrolo[2,3 dl pyrimidin-4-vll-2-hydroxymethyl-phenyl)-benzamide 0 HN HO N F N N 0
H
WO 2013/008095 PCT/IB2012/001699 - 79 (1) 4-tert-Butyl-N-(2-(tert-butyl-d iphenyl-silanyloxymethyl)-3-{6-[1 -(2-fluoro-acetyl) 1, 2,3,6-tetrahyd ro-pyrid in-4-yll-7H-pyrrolo[2,3-dipyrimid in-4-yll-phenyl)-benzamide, Intermediate 32 0 HN Si O N N0F H To a solution of Intermediate 30 (100 mg, 0.139 mmol) in pyridine (5 ml) was added fluoro-acetyl chloride (20 mg, 0.208 mmol). The mixture was stirred at r.t. for 20 hrs, then the solvent was removed in vacuo. The crude product was purified using flash chromatography (siliga gel, EtOAc/MeOH/NH 3 gradient) to obtain Intermediate 32. (2) 4-tert-Butyl-N-(3-{6-[1-(2-fluoro-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yll-7H pyrrolo[2,3-dl pyrimidin-4-yll-2-hyd roxymethyl-phenyl)-benzamide 0 HN HO NN F N N 0 H Example 38 was prepared analogue to Example 37 step 8 by replacing Intermediate 31 with Intermediate 32. MS (ESI): 542 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.46 (br s, 1H), 10.52 (s, 1H), 8.83 (s, 1H), 8.21 (d, 1H), 7.90 (d, 2H), 7.59 (d, 2H), 7.50 (t, 1H), 7.34 (d, 1H), 6.61 (br, WO 2013/008095 PCT/IB2012/001699 - 80 s), 6.44 (s, 1H), 5.91 (br s, 1H), 5.25 (m, 2H), 4.67 (s, 2H), 4.18 (m, 1H), 4.08 (m, 1H), 3.67 (m, 1H), (3.47 m, 1H), 2.57 (m, 1H), 2.51 (m, 1H), 1.32 (s, 9H). Example 39 4-(4-{5-Fluoro-3-[2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylaminol-2-methyl-phenyll 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide OH 0 HN F N N N N N H / (1) 4-Chlorocarbonyl-3-fluoro-benzoic acid methyl ester, Intermediate 33 0 S 0 Cl 0 F 2-Fluoro-terephthalic acid 4-methyl ester (J. Med. Chem., 52(19), 5950-5966; 2009) (500 mg, 2.25 mmol) was suspended in DCM (10 ml). Then oxalyl chloride (5.08 ml, 58.0 mmol) and a drop of DMF were added. The resulting mixture was refluxed for 14 hrs. The solvents were removed in vacuo, and the resulting crude Intermediate 33 was used in the next step without purification.
WO 2013/008095 PCT/IB2012/001699 - 81 (2) N-(3-Bromo-5-fluoro-2-methyl-phenyl)-3-fluoro-terephthalamic acid methyl ester, Intermediate 34 0 HI | Br s N / 0 F F 3-Bromo-5-fluoro-2-methylaniline (515 mg, 2.53 mmol) was dissolved in pyridine (20 ml). Then Intermediate 33 (547 mg, 2.53 mmol) and DMAP (3.09 mg, 0.025 mmol) were added and the resulting mixture was stirred at r.t. for 2 hrs. The solvents were removed in vacuo and the residue was taken up with EtOAc and H 2 0. The organic layer was washed with sat. NaHCO 3 solution and brine, and then dried over Na 2
SO
4 . The solvents were removed in vacuo and the resulting residue was recrystallized with MeOH to afford Intermediate 34 as colorless solid. (3) N-(3-Bromo-5-fluoro-2-methyl-phenyl)-2-fluoro-4-(1-hydroxy-1-methyl-ethyl) benzamide, Intermediate 35 OH H | Br" N / 0 F F Intermediate 34 (75 mg, 0.195 mmol) was dissolved in THF (10 ml) and the resulting mixture was cooled to 00C. Then methyl magnesium bromide (0.390 ml, 1.17 mmol) was added dropwise and stirring was continued for 3 hrs. The mixture was concentrated to dryness and then diluted with MeOH/DMSO. The resulting precipitate was filterd off to give Intermediate 35 as a white solid. MS (ESI): 384 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 10.04 (brs, 1H),.7.63 (m, 1H), 7.42 (m, 2H), 7.36 (m, 2H), 5.27 (s, 1H), 2.24 (s, 3H), 1.40 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 82 (4) 2-Fluoro-N-[5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1, 3,21d ioxaborolan-2-yl) phenyll-4-(1-hydroxy-1-methyl-ethyl)-benzamide, Intermediate 36 OH 9 H | O'B N / 0 F F Intermediate 36 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with Intermediate 35. (5) 4-(4-{5-Fluoro-3-[2-fluoro-4-(1 -hyd roxy- 1 -methyl-ethyl)-benzoylamino-2-methyl phenyll-7H-pyrrolo[2,3-dl pyrimid in-6-yl)-3,6-d ihyd ro-2H-pyrid ine-1 -carboxylic acid dimethylamide OH 0 HN F N N N N N H / Example 39 was prepared analogue to Example 37 by replacing the boronic ester Intermediate 28 in step 5 with the boronic ester Intermediate 36. MS (ESI): 575 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (s, 1H), 9.93 (s, 1H), 8.83 (s, 1H), 7.74 (m, 1H), 7.64 (d, 1H), 7.43 (m, 2H), 7.18 (dd, 1H), 6.60 (s, 1H), 6.34 (s, 1H), 5.30 (s, 1H), 3.90 (m, 2H), 3.33 (m, 2H), 2.77 (s, 6H), 2.54 (m, 2H), 2.15 (s, 3H), 1.46 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 83 Example 40 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 dl pvrimidin-4-vll-phenyl-benzamide 0 HN F N H NN SN N HH (1) N-(3-Bromo-5-fluoro-2-methyl-phenyl)-4-tert-butyl-benzamide, Intermediate 37 H l Br N 0 F Intermediate 37 was prepared analogue to Intermediate 34 by replacing Intermediate 33 with 4-tert-butyl-benzoyl chloride. MS (ESI): 364 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 10.11 (br s, 1H), 7.90 (d, 2H), 7.55 (d, 2H), 7.49 (d, 1H), 7.32 (d, 1H), 2.32 (s, 3H), 1.38 (s, 9H). (2) 4-tert-Butyl-N-[5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,21dioxaborolan-2-yl) phenyll-benzamide, Intermediate 38 0 B Nr 0~0
F
WO 2013/008095 PCT/IB2012/001699 - 84 Intermediate 38 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with Intermediate 37. MS (ESI): 412 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.85 (br s, 1H), 7.90 (d, 2H), 7.55 (d, 2H), 7.35 (d, 1H), 7.22 (d, 1H), 2.35 (s, 3H), 1.40 (s, 6H), 1.32 (m, 15H). (3) 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-dl pvrimidin-4-vll-phenyl-benzamide CI 0 HN F N NH N H Example 40 was prepared analogue to Intermediate 30 in Example 37 step 6 by replacing Intermediate 28 in Example 37 step 5 with Intermediate 38. MS (ESI): 484 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.55 (s, 1H), 9.98 (s, 1H), 8.85 (s, 1H), 8.71 (br s, 1H), 7.92 (d, 2H), 7.56 (d, 2H), 7.50 (m, 1H), 7.18 (m, 1H), 6.56 (m, 1H), 6.43 (s, 1H), 3.80 (m, 2H), 3.28 (m, 2H), 2.67 (m, 2H), 2.10 (s, 3H), 1.32 (s, 9H). Example 41 4-{4-[3-(4-tert-Butyl-benzoylamino)-5-fluoro-2-methyl-phenyll-7H-pyrrolo[2,3-dlpyrimidin 6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide CI 0 HN F II HN4 N N N- WO 2013/008095 PCT/IB2012/001699 - 85 Example 41 was prepared analogue to Example 37 step 7 by replacing Intermediate 30 with Example 40. MS (ESI): 555 [M+H]* , 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (s, 1H), 9.98 (s, 1H), 8.83 (s, 1H), 7.95 (d, 2H), 7.58 (d, 2H), 7.48 (m, 1H), 7.22 (m, 1H), 6.60(s, 1H), 6.33 (s, 1H), 5.30 (s, 1H), 3.90 (m, 2H), 3.32 (m, 2H), 2.77 (s, 6H), 2.55 (m, 2H), 2.12 (s, 3H), 1.34 (s, 9H). Example 42 4-tert-Butyl-N-{5-fluoro-3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-d] pvrimidin-4-ll-2-methyl-phenyl-benzamide 0 HN F 0 N-S =O N N H To a solution of Example 40 (90 mg, 0.186 mmol) and DIPEA (0.098 ml, 0.558 mmol) in THF (10 ml) was added methanesulfonyl chloride (0.015 ml, 0.186 mmol) dropwise. The resulting mixture was stirred at r.t. for 1 hr, then quenched with water and diluted with EtOAc. The organic layer was washed with sat. aqueous NaHCO 3 solution and brine, dried with Na 2
SO
4 , and filtered. The solvents were removed in vacuo, and the crude product was purified by reversed phase HPLC (MeCN/H 2 0 gradient) to yield Example 42 as a light yellow solid. MS (ESI): 562 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.48 (br s, 1H), 9.97 (s, 1H), 8.82 (s, 1H), 7.93 (d, 2H), 7.56 (d, 2H), 7.46 (m, 1H), 7.19 (m, 1H), 6.61 (s, 1H), 6.36 (s, 1H), 3.92 (m, 2H), 3.31 (m, 2H), 2.94 (s, 3H), 2.62 (m, 2H), 2.10 (s, 3H), 1.31 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 - 86 Example 43 4-tert-Butyl-N-{3-[6-(1-dimethylsulfamoyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-5-fluoro-2-methyl-phenyll-benzamide - 0 HN F N- -N N N O1 H 0 Example 43 was prepared analogue to Example 42 by replacing methanesulfonyl chloride with N,N-dimethylamidosulfamoyl chloride. MS (ESI): 591 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.48 (br s, 1H), 9.97 (s, 1H), 8.82 (s, 1H), 7.93 (d, 2H), 7.56 (d, 2H), 7.46 (m, 1H), 7.20 (m, 1H), 6.59 (s, 1H), 6.34 (s, 1H), 3.93 (m, 2H), 3.40 (m, 2H), 2.76 (s, 6H), 2.57 (m, 2H), 2.09 (s, 3H), 1.31 (s, 9H). Example 44 4-tert-Butyl-N-{3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-2-methyl-phenyll-benzamide 0 HN 0 N-7=O N N
H
WO 2013/008095 PCT/IB2012/001699 - 87 (1) 4-tert-Butyl-N-{2-methyl-3-[6-(1,2,3,6-tetrahyd ro-pyridin-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-phenyll-benzamide, Intermediate 39 - 0 HN NH N N H Intermediate 39 was prepared analogue to Intermediate 30 in Example 37 step 6 by replacing Intermediate 28 in Example 37 step 5 with Intermediate 48. MS (ESI): 465 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.29 (br s, 1H), 9.92 (s, 1H), 8.78 (s, 1H), 7.94 (d, 2H), 7.53 (d, 2H), 7.45 (m, 1H), 7.37 (m, 2H), 6.60 (br s, 1H), 6.20 (s, 1H), 3.40 (m, 2H), 2.88 (m, 2H), 2.32 (m, 2H), 2.13 (s, 3H), 1.31 (s, 9H). (2) 4-tert-Butyl-N-{3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-dl pvrimidin-4-ll-2-methyl-phenyl-benzamide 0 HN 0 N-S=O N N H To a solution of Intermediate 39 (80 mg, 0.172 mmol) and TEA (0.048 ml, 0.344 mmol) in DCM was added methanesulfonyl chloride (0.021 ml, 0.258 mmol) dropwise. The resulting mixture was stirred at r.t. for 16 hrs, then quenched with water, and extracted with EtOAc. The organic layer was dried with Na 2
SO
4 and filtered. The solvents were removed in vacuo, and the crude product was purified by flash chromatography (silica gel, EtOAc/MeOH/NH 3 gradient) to yield Example 44.
WO 2013/008095 PCT/IB2012/001699 - 88 MS (ESI): 544 [M+H]*, 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.34 (brs, 1H), 9.92 (s, 1H), 8.81 (s, 1H), 7.94 (d, 2H), 7.54 (d, 2H), 7.46 (m, 1H), 7.37 (m, 2H), 6.60 (br s, 1H), 6.31 (s, 1H), 3.92 (m, 2H), 3.36 (m, 2H), 2.93 (s, 3H), 2.61 (m, 2H), 2.14 (s, 3H), 1.32 (s, 9H). Example 45 4-{4-[3-(6-tert-Butyl-1-oxo-3,4-dihvdro-1 H-isoquinolin-2-yl)-2-hydroxymethyl-phenyll-7H pyrrolo[2,3-dlpyrimidin-6-vll-3,6-dihvdro-2H-pyridine-1-carboxylic acid dimethylamide O N N N N H NH OH N (1) Acetic acid 2-(6-tert-butyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-6-(4,4,5,5 tetramethyl-[ 1,3,21d ioxaborolan-2-yl)-benzyl ester, Intermediate 40 o 1 0 O- N B Intermediate 40 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with acetic acid 2-bromo-6-(6-tert-butyl-1-oxo-3,4 dihydro-1 H-isoquinolin-2-yl)-benzyl ester (W02010/000633).
WO 2013/008095 PCT/IB2012/001699 - 89 (2) 4-{4-[3-(6-tert-Butyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-2-hydroxymethyl phenyll-7H-pyrrolo[2,3-dlpyrimidin-6-yll-3,6-dihydro-2H-pyridine-1 -carboxylic acid dimethylamide N N N ~- N NH N Example 45 was prepared analogue to Intermediate 6 by replacing Intermediate 5 with Intermediate 40. MS (ESI): 579 [M+H]* ,H-NMR (DMSO-d 6 ): 6 (ppm) 8.83 (s, 1H), 7.88 (m, 1H), 7.68 (m, 1H), 7.58 (m, 1H), 7.44 (m, 1H), 7.42 (m, 1H), 6.61 (s, 1H), 6.58 (s, 1H), 5.24 (m, 1H), 4.39 (m, 2H), 4.02 (m, 1H), 3.92 (m, 2H), 3.89 (m, 1H), 3.36 (m, 2H), 3.29 (m, 1H), 3.13 (m, 1H), 2.78 (s, 6H), 2.55 (m, 2H), 1.33 (s, 9H). Example 46 4-{4-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-2-hydroxymethyl-phenyll 7H-pyrrolo[2,3-dl pyrimidin-6-yll-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O N NH N O ,: -- N NH OHN N WO 2013/008095 PCT/IB2012/001699 - 90 (1) Acetic acid 2-(6-cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-6-(4,4,5,5 tetramethyl-[1, 3,21d ioxaborolan-2-yl)-benzyl ester, Intermediate 41 o 1 0 O- N B Intermediate 41 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with acetic acid 2-bromo-6-(6-cyclopropyl-1-oxo-3,4 dihydro-1 H-isoquinolin-2-yl)-benzyl ester (W02010/000633). (2) 4-{4-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-2-hyd roxymethyl phenyll-7H-pyrrolo[2,3-dlpyrimidin-6-yll-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O N N N N NH O N Example 46 was prepared analogue to Intermediate 6 by replacing Intermediate 5 with Intermediate 41. MS (ESI): 563 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 8.81 (s, 1H), 7.80 (d, 1H), 7.66 (d, 1H), 7.56 (t, 1H), 7.50 (d, 1H), 7.09 (m, 1H), 7.08 (m, 1H), 6.60 (s, 1H), 6.54 (s, 1H), 5.15 (m, 1H), 4.36 (m, 2H), 3.98 (m, 1H), 3.91 (m, 2H), 3.89 (m, 1H), 3.35 (m, 2H), 3.24 (m, 1H), 3.09 (m, 1H), 2.77 (s, 6H), 2.55 (m, 2H), 2.00 (m, 1H), 1.04 (m, 2H), 0.78 (m, 2H).
WO 2013/008095 PCT/IB2012/001699 - 91 Example 47 4-(4-{2-Hydroxymethyl-3-[6-(1-hydroxy-1-methyl-ethyl)-1-oxo-3,4-dihydro-1 H-isoquinolin 2-vll-phenyll-7H-pvrrolo[2,3-dlpyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O N N O / - N NH HO OHN N (1) 2-Bromo-6-[6-(1-hydroxy-1-methyl-ethyl)-1-oxo-3,4-dihydro-1H-isoguinolin-2-yll benzaldehyde, Intermediate 42 0 / N Br 0 HO To a mixture of 2,6-dibromo-benzaldehyde (1.60 g, 6.06 mmol), Pd 2 (dba) 3 (222 mg, 0.243 mmol), xantphos (210 mg, 0.364 mmol), and Cs 2
CO
3 (2.77 g, 8.49 mmol) in dioxane (60 ml) under argon was added 6-(1-hydroxy-1-methyl-ethyl)-3,4-dihydro-2H isoquinolin-1-one (US2009/0306041) (995 mg, 4.85 mmol). The resulting mixture was refluxed overnight. After cooling down to r.t., water was added, and the mixture was extracted three times with EtOAc. The combined organic layers were dried, filtered, and evaporated to dryness. The crude product was purified by flash chromatography (silica gel, cyclohexane/EtOAC gradient) to yield Intermediate 42.
WO 2013/008095 PCT/IB2012/001699 - 92 (2) 2-(3-Bromo-2-hydroxymethyl-phenyl)-6-( -hydroxy-1 -methyl-ethyl)-3,4-dihydro 2H-isoguinolin-1-one, Intermediate 43 0 / 1 N Br OH HO To a solution of Intermediate 42 (320 mg, 0.824 mmol) in THF (10 ml) under argon atmosphere was added lithium triethylborohydride (1M in THF, 0.989 ml, 0.989 mmol) dropwise. The resulting mixture was stirred for 2 hrs at r.t. before adding sat. aqueous NaHCO 3 solution (5 ml). Additional water was added and the mixture was extracted three times with EtOAc. The combined organic layers were dried, filtered, and evaporated to dryness. The crude product was purified by flash chromatography (silica gel, cyclohexane/EtOAC gradient) to yield Intermediate 43. MS (ESI): 390 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 7.83 (d, 1H), 7.63 (d, 1H), 7.48 (m, 1H), 7.47 (s, 1H), 7.36 (m, 1H), 7.34 (m, 1H), 5.16 (s, 1H), 4.92 (m, 1H), 4.53 (m, 1H), 4.46 (m, 1H), 3.96 (m, 1H), 3.77 (m, 1H), 3.25 (m, 1H), 3.07 (m, 1H), 1.45 (s, 6H). (3) Acetic acid 2-bromo-6-[6-( -hydroxy-1 -methyl-ethyl)-1 -oxo-3,4-dihydro-1 H isoquinolin-2-yll-benzyl ester, Intermediate 44 0 / I N Br 0 HOO To a solution of Intermediate 43 (238 mg, 0.610 mmol) in DCM (6 ml) were added TEA (0.085 ml, 0.610 mmol), DMAP (7.5 mg, 0.061 mmol), and acetic anhydride (62 mg, 0.610 mmol). The resulting mixture was stirred for 24 hrs at r.t. The solvents were removed in vacuo and the crude product was purified by flash chromatography (silica gel, cyclohexane/EtOAC gradient) to yield Intermediate 44. MS (ESI): 432 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 7.82 (d, 1H), 7.70 (m, 1H), 7.47 (m, 3H), 7.44 (m, 1H), 5.16 (s, 1H), 5.11 (m, 1H), 5.04 (m, 1H), 4.03 (m, 1H), 3.67 (m, 1H), 3.18 (m, 1H), 3.09 (m, 1H), 1.97 (s, 3H), 1.45 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 93 (4) Acetic acid 2-[6-(1-hydroxy-1-methyl-ethyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2 yll-6-(4,4,5,5-tetramethyl-[1, 3,21d ioxaborolan-2-yl)-benzyl ester, Intermediate 45 0 NB' 0_ HO O Intermediate 45 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with Intermediate 44. MS (ESI): no peaks, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 7.82 (d, 1H), 7.66 (m, 1H), 7.48-7.46 (m, 4H), 5.29 (d, 1H), 5.15 (s, 1H), 4.99 (d, 1H), 4.02 (m, 1H), 3.65 (m, 1H), 3.16 (m, 1H), 3.09 (m, 1H), 1.92 (s, 3H), 1.45 (s, 6H), 1.31 (s, 12H). (5) 4-(4-{2-Hydroxymethyl-3-[6-( -hydroxy-1-methyl-ethyl)-1 -oxo-3,4-dihydro-1 H isoquinolin-2-yll-iphenyll-7H-ipyrrolo[2,3-d1 pyri mid in-6-yl)-3,6-d ihydro-2 H-pyrid ine-1 carboxylic acid dimethylamide N N NH N HO OHN N Example 47 was prepared analogue to Intermediate 6 by replacing Intermediate 5 with Intermediate 45, followed by basic removal of the acetate protecting group with LiOH in MeOH/water. MS (ESI): 581 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.47 (br s, 1H), 8.82 (s, 1H), 7.86 (d, 1H), 7.66 (d, 1H), 7.57 (t, 1H), 7.49 (m, 3H), 6.60 (s, 1H), 6.55 (s, 1H), 5.21 (m, 1H), 5.16 (s, 1H), 4.37 (m, 2H), 4.02 (m, 1H), 3.90 (m, 2H), 3.35-3.25 (m, 3H), 3.13 (m, 1H), 2.77 (s, 6H), 2.55 (m, 2H), 1.46 (s, 6H).
WO 2013/008095 PCT/IB2012/001699 - 94 Example 48 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll-2 hydroxymethyl-phenyll-benzamide .0 HN HO N N H Example 48 was prepared analogue to Intermediate 29 by replacing Intermediate 1 with Intermediate 11, followed by removal of the TBDPS protecting group with TBAF in THF. MS (ESI): 483 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (br s, 1H), 10.52 (s, 1H), 8.82 (s, 1H), 8.21 (d, 1H), 7.90 (d, 2H), 7.58 (d, 2H), 7.50 (t, 1H), 7.35 (d, 1H), 6.64 (br s, 1H), 6.42 (s, 1H), 5.91 (m, 1H), 4.68 (d, 2H), 4.28 (m, 2H), 3.81 (m, 2H), 2.46 (m, 2H), 1.32 (s, 9H). Example 49 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d1pyrimidin-4-yll-5-fluoro 2-methyl-phenyll-benzamide HN F
H
WO 2013/008095 PCT/IB2012/001699 - 95 Example 49 was prepared analogue to Intermediate 6 by replacing Intermediate 3 with Intermediate 11 and Intermediate 5 with Intermediate 38. MS (ESI): 485 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.44 (br s, 1H), 9.97 (s, 1H), 8.82 (s, 1H), 7.94 (d, 2H), 7.57 (d, 2H), 7.50(m, 1H), 7.20 (m, 1H), 6.64 (s, 1H), 6.32 (s, 1H), 4.28 (s, 2H), 3.80 (m, 2H), 2.47 (m, 2H), 2.11 (s, 3H), 1.32 (s, 9H). Example 50 N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d1pyrimid in-4-yll-5-fluoro-2-methyl phenyll-4-dimethylamino-benzamide N N O N F 7 NN - 0 N N H (1) N-(3-Bromo-5-fluoro-2-methyl-phenyl)-4-dimethylamino-benzamide, Intermediate 46 *H Br N F Intermediate 46 was prepared analogue to Intermediate 34 by replacing Intermediate 33 with 4-dimethylamino-benzoyl chloride. MS (ESI): 353 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.77 (br s, 1H), 7.85 (d, 2H), 7.45 (d, 1H), 7.31 (d, 1H), 6.77 (d, 2H), 3.00 (s, 6H), 2.24 (s, 3H).
WO 2013/008095 PCT/IB2012/001699 - 96 (2) 4-Dimethylamino-N-[5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-[1, 3,21d ioxaborolan 2-yl)-phenyll-benzamide, Intermediate 47 N IH O BN 0 0 0 F Intermediate 47 was prepared analogue to Intermediate 4 by replacing 1-bromo-5 fluoro-2-methyl-3-nitro-benzene with Intermediate 46. (3) N-{3-[6-(3,6-Dihyd ro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dl pyrimid in-4-yll-5-fluoro-2 methyl-phenyll-4-dimethylamino-benzamide N - 0 HN F H Example 50 was prepared analogue to Example 49 by replacing Intermediate 38 with Intermediate 47. MS (ESI): 472 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.43 (br s, 1H), 9.64 (s, 1H), 8.82 (s, 1H), 7.88 (d, 2H), 7.46 (d, 1H), 7.15 (d, 1H), 6.78 (d, 2H), 6.64 (s, 1H), 6.31 (s, 1H), 4.28 (s, 2H), 3.80 (m, 2H), 3.00 (s, 6H), 2.47 (m, 2H), 2.10 (s, 3H).
WO 2013/008095 PCT/IB2012/001699 - 97 Example 51 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-dlpVrimidin-4-yll-2 methyl-phenyll-benzamide H N - 0 N N H (1) 4-tert-Butyl-N-[2-methyl-3-(4,4,5,5-tetramethyl-[1,3,21dioxaborolan-2yl)-phenyll benzamide, Intermediate 48 H N N-. ,'B,0 O- 0 To a solution of 2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (370.0 g, 1.58 mol) in DCM (4 I) and triethylamin (330 ml, 2.38 mol), 4-tert-butylbenzoyl chloride (290 ml, 1.58 mol) was added dropwise over 25 minutes at 00C. The mixture was stirred at room temperature for 1 hour. The mixture was washed with water, saturated sodium hydrogen carbonate solution and brine. The organic layer was dried over sodium sulfate and evaporated. The residue was taken up in heptane (1 I) and stirred at room temperature for 1 hour. The solid was filtered off and dried to afford Intermediate 48 as a beige solid. MS (ESI): 394 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.80 (s, 1H), 7.92 (d, 2H), 7.56 (d, 2H), 7.38 (m, 2H), 7.20 (m, 1H), 2.36 (s, 3H), 1.31 (s, 21 H).
WO 2013/008095 PCT/IB2012/001699 - 98 (2) 4-tert-Butyl-N-{3-[6-(3,6-d ihydro-2-H-thiopyran-4-yl)-7H-pyrrolo[2,3-dipyrimid in-4 yll-2-methyl-phenyll-benzamide H N '- 0 N / N N H For the Suzuki coupling between chloride Intermediate 15 (0.25 g, 0.99 mmol) and the boronic ester Intermediate 48 (0.78 g, 1.98 mmol) the same protocol was used as described in Example 1 step 1 to afford Example 51 as a beige solide. MS (ESI): 483 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.33 (br s, 1H), 9.91 (s, 1H), 8.80 (s, 1H), 7.93 (d, 2H), 7.59 (m, 1H), 7.55 (d, 2H), 7.38 (m, 2H), 6.76 (m, 1H), 6.29 (s, 1H), 3.35 (m, 2H), 2.82 (m, 2H), 2.64 (m, 2H), 2.14 (s, 3H), 1.32 (s, 9H). Example 52 4-tert-Butyl -N-{2-methyl-3-[6-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 dlpyrimidin-4-yll-phenyl}-benzamide. H | N - 0 N S=O N N H Compound of Example 51 (240 mg, 0.50 mmol) was dissolved in acetic acid (5 ml) and hydrogen peroxide (0.051 ml, 0.50 mmol) was added. The mixture was stirred at room temperature for 4 hours. The mixture was treated with sodium hydrogen sulfite solution 10 % (10 ml) for 10 minutes, diluted with water, basified with 2N sodium hydroxide solution and extracted with EtOAc. The organic layer was washed with brine (2x), dried WO 2013/008095 PCT/IB2012/001699 - 99 over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc to EtOAc/MeOH/NH 4 0H 9:1:0.1 to EtOAc/MeOH/NH 4 OH4 8:2:0.2) to afford the compound Example 52 as a beige solid. MS (ESI): 499 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.45 (br s, 1H), 9.95 (s, 1H), 8.84 (s, 1H), 7.96 (d, 2H), 7.57 (d, 2H), 7.52 (m, 1H), 7.41 (m, 2H), 6.49 (br s, 1H), 6.42 (s, 1H), 3.72 (m, 1H), 3.49 (m, 1H), 3.15 (m, 1H), 2.96 (m, 1H), 2.89 (m, 1H), 2.77 (m, 1H), 2.17 (s, 3H), 1.34 (s, 9H). Example 53 4-tert-Butyl -N-{3-[6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 dl pyrimidin-4-yll-2-methyl-phenyll-benzamide. H | N - 0 0 O
S
N N N -,N H Compound of Example 51 (250 mg, 0.51 mmol) was dissolved in DCM (5 ml), then trifluoro acetic acid (5 ml) and hydrogen peroxide (0.079 ml, 0.78 mmol) were added. The mixture was stirred at room temperature for 2 hours. The mixture was treated with sodium hydrogen sulfite solution 10 % (10 ml) for 10 minutes, diluted with water, basified with 2N sodium hydroxide solution and extracted with EtOAc. The organic layer was washed with brine (2x), dried over sodium sulfate, filtered and evaporated. The residue was purified by flash chromatography on silica (EtOAc to EtOAc/MeOH/NH 4 0H 98:2:0.2) to afford the compound Example 53 as a beige solid. MS (ESI): 515 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.47 (br s, 1H), 9.93 (s, 1H), 8.84 (s, 1H), 7.94 (d, 2H), 7.60 (m, 1H), 7.56 (d, 2H), 7.49 (m, 1H), 7.40 (m, 1H), 6.48 (m, 1H), 6.43 (s, 1H), 4.00 (m, 2H), 3.36 (m, 2H), 3.07 (m, 2H), 2.16 (s, 3H), 1.33 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 -100 Example 54 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.51dec-7-en-8-l)-7H-pyrrolo[2,3-d]pyrimidin-4-yll-2 hydroxymethyl-phenyll-benzamide .0 HN HO 7N % H Example 54 was prepared analogue to Intermediate 29 by replacing Intermediate 1 with Intermediate 17, followed by removal of the TBDPS protecting group with TBAF in THF. MS (ESI): 539 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.34 (br s, 1H), 10.51 (s, 1H), 8.80 (s, 1H), 8.21 (d, 1H), 7.90 (d, 2H), 7.59 (d, 2H), 7.49 (t, 1H), 7.33 (d, 1H), 6.48 (m, 1H), 6.39 (s, 1H), 5.90 (m, 1H), 4.67 (m, 2 H), 3.91 (m, 4H), 2.57 (m, 2H), 2.42 (m, 2H), 1.79 (m, 2H), 1.32 (s, 9H). Example 55 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yll-2 hydroxymethyl-phenyll-benzamide s O HN HO OH N
N
WO 2013/008095 PCT/IB2012/001699 - 101 (1) 4-tert-Butyl-N-{2-hyd roxymethyl-3-[6-(4-oxo-cyclohex- 1 -enyl)-7H-pyrrolo[2,3 dl pyrimidin-4-vll-phenyll-benzamide, Intermediate 49 0 HN HO N N H Intermediate 49 was prepared analogue to Intermediate 19 by replacing Example 27 with Example 54. MS (ESI): 495 [M+H]* (2) 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-dipyrimidin-4-yll 2-hydroxymethyl-phenyl}-benzamide 0 HN HO OH N N H To a solution of Intermediate 49 (80 mg, 0.162 mmol) in MeOH/DCM (1:1) were added cerium(Ill) chloride heptahydrate (66.3 mg, 0.178 mmol) and NaBH 4 (6.1 mg, 0.162 mmol). The resulting mixture was stirred at r.t. for 2 hrs. Water was added, and the mixture was extracted three times with DCM/isopropanol (3:1). The combined organic layers were dried, filtered, and evaporated to dryness. The resulting residue was purified using flash chromatography (silica gel, EtOAc/MeOH/NH 3 gradient) to yield Example 55.
WO 2013/008095 PCT/IB2012/001699 - 102 MS (ESI): 497 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.29 (br s, 1H), 10.51 (s, 1H), 8.79 (s, 1H), 8.19 (d, 1H), 7.90 (d, 2H), 7.59 (d, 2H), 7.49 (t, 1H), 7.34 (d, 1H), 6.49 (m, 1H), 6.35 (s, 1H), 5.89 (m, 1H), 4.72 (m, 1H), 4.67 (m, 2 H), 3.80 (m, 1H), 2.65-2.35 (m, 3H), 2.11 (m, 1H), 1.84 (m, 1H), 1.59 (m, 1H), 1.33 (s, 9H). Example 56 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1-enyl)-7H-pyrrolo[2,3-dipyrimidin-4-yll-2 hydroxymethyl-phenyll-benzamide 0 N NH OH N /N N N H To a solution of Intermediate 49 (100 mg, 0.202 mmol) in DCM/MeOH/AcOH (4 ml, 100:93:7) was added dimethylamine (91 mg, 2.02 mmol). The mixture was stirred for 15 min at r.t. before adding sodium cyanoborohydride (12.7 mg, 0.202 mmol). The mixture was stirred at r.t. overnight and then quenched with 2N HCI (3 ml). After additional stirring for 30 min water and 2N NaOH were added. The mixture was extracted with EtOAc, and the organic layer was dried, filtered, and evaporated to dryness. The resulting residue was purified using flash chromatography (silica gel, EtOAc/MeOH/NH 4 0H gradient) to yield Example 56. MS (ESI): 524 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.31 (br s, 1H), 10.51 (s, 1H), 8.79 (s, 1H), 8.19 (m, 1H), 7.90 (d, 2H), 7.59 (d, 2H), 7.49 (t, 1H), 7.34 (d, 1H), 6.57 (m, 1H), 6.35 (s, 1H), 5.89 (m, 1H), 4.66 (m, 2H), 2.60-2.15 (m, 5H), 2.27 (m, 3H), 1.99 (m, 1H), 1.48 (m, 1H), 1.31 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 -103 Example 57 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-aminol-5-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-dipyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O N O HN F N 0 N4 N N N H / A mixture of Intermediate 6 (50 mg, 0.127 mmol), 4-nitrophenylchloroformate (25.6 mg, 0.127 mmol), pyridine (12 mg, 0.152 mmol), and DMAP (1.5 mg, 0.013 mmol) in THF (2 ml) was stirred ar r.t. for 5 hrs. Then additional 4-nitrophenylchloroformate (25.6 mg, 0.127 mmol) was added and stirring at r.t. was continued for 72 hrs. Then pyridine (100 mg, 1.27 mmol) and 3-tert-butoxy-azetidine hydrochloride (US2009/0105209) (105 mg, 0.634 mmol) were added and the mexture was stirred for 1 hr. The mixture was diluted into EtOAc and aqueous NH 4 0H solution (2 M). The organic layer was washed with brine, dried with Na 2
SO
4 , filtered, and evaporated to dryness. The crude product was purified by flash chromatography (siliga gel, EtOAc/MeOH gradient) to afford Example 57 as beige solid. MS (ESI): 550 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.45 (br s, 1H), 8.80 (s, 1H), 7.97 (br s, 1H), 7.44 (m, 1H), 7.00 (m, 1H), 6.57 (br s, 1H), 6.27 (s, 1H), 4.52 (m, 1H), 4.17 (m, 2H), 3.87 (m, 2H), 3.75 (m, 2H), 3.30 (m, 2H), 2.74 (s, 6H), 2.49 (m, 2H), 2.03 (s, 3H), 1.13 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 -104 Example 58 4-(4-{5-Fluoro-3-[(3-isopropoxy-azetidine-1-carbonVl)-aminol-2-methVl-phenVl}-7H pyrrolo[2,3-dlpyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O " N O HN F N N N N N H / Example 58 was prepared analogue to Example 57 by replacing 3-tert-butoxy-azetidine hydrochloride with 3-isopropoxy-azetidine hydrochloride. MS (ESI): 536 [M+H]* , 1 H-NMR (CDCl 3 ): 6 (ppm) 12.24 (br s, 1H), 8.86 (s, 1H), 7.78 (m, 1H), 6.93 (m, 1H), 6.49 (m, 1H), 6.33 (s, 1H), 6.28 (m, 1H), 4.39 (m, 1H), 4.24 (m, 2H), 4.03 (m, 2H), 3.97 (m, 2H), 3.62 (m, 1H), 3.47 (m, 2H), 2.86 (s, 6H), 2.62 (m, 2H), 2.11 (s, 3H), 1.16 (d, 6H). Example 59 5-Fluoro-1,3-dihydro-isoindole-2-carboxylic acid {3-[6-(1-dimethylcarbamoyl-1,2,3,6 tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3-dlpyrimidin-4-vll-5-fluoro-2-methyl-phenyll-amide
-
N H N / N F N-
-
N N , 0 F 0 Example 59 was prepared analogue to Example 57 by replacing 3-tert-butoxy-azetidine hydrochloride with 5-fluoro-2,3-dihydro-1 H-isoindole. MS (ESI): 558 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.40 (br s, 1H), 8.81 (s, 1H), 7.96 (s, 1H), 7.56 (m, 1H), 7.41 (m, 1H), 7.26 (m, 1H), 7.14 (m, 1H), 7.04 (m, 1H), 6.58 (s, WO 2013/008095 PCT/IB2012/001699 -105 1H), 5.30 (s, 1H), 4.78 (m, 4H), 3.89 (m, 2H), 3.34 (m, 2H), 2.76 (s, 6H), 2.52 (m, 2H), 2.11 (s, 3H). Example 60 4-[4-(5-Fluoro-2-methyl-3-{[3-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-azetidine-1 carbonyl1-amino}-phenyl)-7H-pyrrolo[2,3-dlpyrimidin-6-yll-3,6-dihydro-2H-pyridine-1 carboxylic acid dimethylamide F FF F FF FF N O HN F
N
N N N H / Example 60 was prepared analogue to Example 57 by replacing 3-tert-butoxy-azetidine hydrochloride with 3-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-azetidine hydrochloride (W02009/077334). MS (ESI): 644 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.35 (br s, 1H), 8.76 (s, 1H), 8.10 (s, 1H), 7.39 (m, 1H), 7.00 (m, 1H), 6.54 (m, 1H), 6.23 (s, 1H), 5.63 (m, 1H), 4.75 (m, 1H), 4.25 (m, 2H), 3.87 (m, 2H), 3.85 (m, 2H), 3.82 (m, 2H), 2.72 (s, 6H), 2.46 (m, 2H), 2.01 (s, 3H).
WO 2013/008095 PCT/IB2012/001699 - 106 Example 61 3-tert-Butoxy-azetidine-1-carboxylic acid {3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H pyrrolo[2,3-di pvrimidin-4-ll-5-fluoro-2-methyl-phenyll-amide -O *'N O 00 HN F N N Example 61 was prepared analogue to Example 57 by replacing Intermediate 6 with Intermediate 12. MS (ESI): 480 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.40 (br s, 1H), 8.80 (s, 1H), 7.95 (s, 1H), 7.43 (m, 1H), 7.00 (m, 1H), 6.62 (br s, 1H), 6.26 (s, 1H), 4.52 (m, 1H), 4.27 (m, 2H), 4.18 (m, 2H), 3.79 (m, 2H), 3.75 (m, 2H), 2.44 (m, 2H), 2.04 (s, 3H), 1.13 (s, 9H). Example 62 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-aminol-4-fluoro-phenyll-7H-pvrrolo[2,3 dl pyrimidin-6-yl)-3, 6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide O NF 0 N~ 0 IN N N N H / Example 62 was prepared analogue to Example 57 by replacing Intermediate 6 with Intermediate 10.
WO 2013/008095 PCT/IB2012/001699 -107 MS (ESI): 536 [M+H]*, 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.36 (br s, 1H), 8.77 (s, 1H), 8.49 (m, 1H), 8.33 (s, 1H), 7.90 (m, 1H), 7.39 (m, 1H), 6.88 (s, 1H), 6.59 (s, 1H), 4.53 (m, 1H), 4.21 (m, 2H), 3.91 (m, 2H), 3.78 (m, 2H), 3.37 (m, 2H), 2.77 (s, 6H), 2.60 (m, 2H), 1.14 (s, 9H). Example 63 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-aminol-4-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-dlpyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide ON O F HN N 0 CN N N N H / (1) 4-[4-(3-Amino-4-fluoro-2-methyl-Phenyl)-7H-pyrrolo[2,3-d1 pyrimid in-6-yll-3,6 dihydro-2H-pyridine-1-carboxylic acid dimethylamide, Intermediate 50 F
H
2 N N /
N
N N N H / Intermediate 10 was prepared analogue to Intermediate 6 by replacing Intermediate 5 with 5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl- 1,3,2-d ioxaborolan-2-yl)aniline. MS (ESI): 395 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.28 (br s, 1H), 8.75 (s, 1H), 7.03 (m, 1H), 6.68 (m, 1H), 6.54 (s, 1H), 6.25 (s, 1H), 5.00 (br s, 2H), 3.88 (s, 2H), 3.32 (m, 2H), 2.75 (s, 6H), 2.50 (m, 2H), 2.03 (s, 3H).
WO 2013/008095 PCT/IB2012/001699 - 108 (2) 4-(4-{3-[(3-tert-Butoxy-azetidine-1 -carbonyl)-aminol-4-fluoro-2-methyl-phenyll 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide O N O F HN N N /N N N
N
H / Example 62 was prepared analogue to Example 57 by replacing Intermediate 6 with Intermediate 50. MS (ESI): 550 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.36 (br s, 1H), 8.79 (s, 1H), 8.04 (m, 1H), 7.37 (m, 1H), 7.21 (m, 1H), 6.57 (m, 1H), 6.25 (s, 1H), 4.54 (m, 1H), 4.14 (m, 2H), 3.89 (m, 2H), 3.70 (m, 2H), 3.32 (m, 2H), 2.75 (s, 6H), 2.50 (m, 2H), 2.13 (s, 3H), 1.14 (s, 9H). Example 64 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d1pyrimidin-4-yll-2 methyl-phenyll-benzamide 0 HN N N
N
WO 2013/008095 PCT/IB2012/001699 -109 (1) 4-tert-Butyl-N-[2-methyl-3-(7H-pyrrolo[2,3-d1pyrimidin-4-yl)-phenyll-benzamide, Intermediate 51 - 0 HN N N N H Intermediate 51 was prepared analogue to Intermediate 6 by replacing Intermediate 3 with 6-chloro-7-deazapurine and Intermediate 5 with Intermediate 48. MS (ESI): 385 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.22 (br s, 1H), 9.94 (s, 1H), 8.82 (s, 1H), 7.94 (d, 2H), 7.60 (m, 1H), 7.58 (d, 2H), 7.37 (m, 1H), 6.30 (m, 1H), 2.12 (s, 3H), 1.31 (s, 9H). (2) N-[3-(7-Benzenesulfonyl-7H-pyrrolo[2,3-dlpyrimidin-4-yl)-2-methyl-phenyll-4-tert butyl-benzamide, Intermediate 52 0 HN N N N 0 To a solution of Intermediate 51 (7.51 g, 19.54 mmol) in THF (500 ml) at 00C was added NaH (1.172 g, 29.3 mmol) portionwise. The mixture was stirred at 00C for 3 hrs, then benzenesulfonyl chloride (3.70 ml, 25.4 mmol) was added and stirring was WO 2013/008095 PCT/IB2012/001699 -110 continued at r.t. overnight. The reaction mixture was quenched with sat. aqueous NH 4 CI solution, and extracted with EtOAc. The organic layer was dried, filtered, and evaporated to dryness. Purification by flash chromatography (silica gel, cyclohexane/EtOAc gradient) yielded Intermediate 52. MS (ESI): 525 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 9.97 (s, 1H), 9.10 (s, 1H), 8.21 (d, 2H), 8.05 (d, 1H), 7.92 (d, 2H), 7.78 (t, 1H), 7.69 (t, 2H), 7.60 (m, 1H), 7.53 (d, 2H), 7.51 (d, 1H), 7.37 (t, 1H), 7.32 (d, 1H), 6.62 (d, 1H), 2.12 (s, 3H), 1.31 (s, 9H). (3) N-[3-(7-Benzenesulfonyl-6-bromo-7H-pyrrolo[2,3-dlpyrimidin-4-yl)-2-methyl phenyll-4-tert-butyl-benzamide, Intermediate 53 0 HN N Br N N -S 0 , To a solution of Intermediate 52 (4.26 g, 8.12 mmol) in THF (150 ml) at -780C was added LDA (1.5 M in THF, 16.24 ml, 24.36 mmol) slowly. The resulting mixture was stirred for 1.5 hrs at -780C before adding a solution of 1,2-dibromo-tetrachloroethane (3.97 g, 12.18 mmol) in THF (1 ml). Stirring was continued at -780C for 2 hrs, then the reaction mixture was quenched by addition of sat. aqueous NH 4 CI solution and warmed up to r.t. The mixture was extracted with EtOAc and the organic layer was dried, filtered, and evaporated to dryness. Purification by flash chromatography (silica gel, cyclohexane/EtOAc gradient) yielded Intermediate 53. MS (ESI): 603 [M+H]* WO 2013/008095 PCT/IB2012/001699 - 111 (4) N-[3-(6-Bromo-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methyl-phenyll-4-tert-butyl benzamide, Intermediate 54 H0 HN Br N N H To a solution of Intermediate 53 (3.82 g, 6.33 mmol) in THF (64 ml) was added a solution of potassium tert-butylate in THF (1 M, 9.49 ml, 9.49 mmol) at 00C. The mixture was stirred at 00C for 1 hr, then an additional solution of potassium tert-butylate in THF (1 M, 2.00 ml, 2.00 mmol) was added and stirring was continued for an additional 1 hr. The reaction was quenched by addition of sat. aqueous NaHCO 3 solution, and the mixture was extracted with EtOAc. The organic layer was dried, filtered, and evaporated to dryness. Purification by flash chromatography (silica gel, cyclohexane/EtOAc gradient) yielded Intermediate 54. MS (ESI): 463 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 13.10 (br s, 1H), 9.97 (s, 1H), 8.82 (s, 1H), 7.93 (d, 2H), 7.54 (d, 1H), 7.48 (d, 1H), 7.40-7.32 (m, 2H), 6.41 (s, 1H), 2.12 (s, 3H), 1.31 (s, 9H). (5) 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll 2-methyl-phenyll-benzamide H0 HN N N
H
WO 2013/008095 PCT/IB2012/001699 -112 Example 64 was prepared analogue to Intermediate 11 by replacing 4-chloro-6-iodo 7H-pyrrolo[2,3-d]pyrimidine with Intermediate 54. MS (ESI): 467 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.33 (br s, 1H), 9.93 (s, 1H), 8.82 (s, 1H), 7.94 (d, 2H), 7.54 (d, 2H), 7.48 (m, 1H), 7.37 (m, 2H), 6.63 (br s, 1H), 6.25 (s, 1H), 4.36 (m, 2H), 3.81 (m, 2H), 2.46 (m, 2H), 2.16 (s, 3H), 1.33 (s, 9H). Example 65 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.51dec-7-en-8-yl)-7H-pyrrolo[2,3-d] pyrimidin-4-yll-2 methyl-phenyll-benzamide - 0 HN O N ,N O H Example 65 was prepared analogue to Intermediate 17 by replacing 4-chloro-6-iodo 7H-pyrrolo[2,3-d]pyrimidine with Intermediate 54. MS (ESI): 523 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.28 (br s, 1H), 9.91 (s, 1H), 8.78 (s, 1H), 7.94 (d, 2H), 7.54 (d, 2H), 7.49 (m, 1H), 7.37 (m, 2H), 6.46 (br s, 1H), 6.23 (s, 1H), 3.90 (s, 4H), 2.55 (m, 2H), 2.41 (m, 2H), 2.14 (s, 3H), 1.79 (m, 2H), 1.31 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 -113 Example 66 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll-2 methyl-phenyll-benzamide - 0 HN OH HO N N (1) 4-tert-Butyl-N-{2-methyl-3-[6-(4-oxo-cyclohex- 1 -enyl)-7H-pyrrolo[2,3-d1pyrimid in 4-yll-phenyll-benzamide, Intermediate 55 - 0 HN
N
N N H Intermediate 55 was prepared analogue to Intermediate 19 by replacing Example 27 with Example 65. MS (ESI): 479 [M+H]*, 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.35 (br s, 1H), 9.92 (s, 1H), 8.78 (s, 1H), 7.94 (d, 2H), 7.53 (d, 2H), 7.49 (m, 1H), 7.36 (m, 2H), 6.64 (br s, 1H), 6.35 (s, 1H), 3.15 (m, 2H), 2.83 (m, 2H), 2.52 (m, 2H), 2.13 (s, 3H), 1.31 (s, 9H).
WO 2013/008095 PCT/IB2012/001699 -114 (2) 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1 -enyl)-7H-pyrrolo[2,3-dlpyrimidin-4-yll 2-methyl-phenyll-benzam ide - 0 HN OH N N H Example 66 was prepared analogue to Example 28 step 2 by replacing Intermediate 19 in with Intermediate 55. MS (ESI): 481 [M+H]* , 1 H-NMR (DMSO-d 6 ): 6 (ppm) 12.21 (br s, 1H), 9.93 (s, 1H), 8.77 (s, 1H), 7.94 (d, 2H), 7.53 (d, 2H), 7.43 (m, 1H), 7.37 (m, 2H), 6.47 (br s, 1H), 6.18 (s, 1H), 4.75 (s, 1H), 3.76 (m, 1H), 2.44 (m, 2H), 2.35 (m, 2H), 2.14 (s, 3H), 1.83 (m, 2H), 1.31 (s, 9H). Example 67 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1-enyl)-7H-pyrrolo[2,3-dipyrimidin-4-yll-2 methyl-phenyll-benzamide H0 HN / N N N H Example 67 was prepared analogue to Example 56 by replacing Intermediate 49 with Intermediate 55.
WO 2013/008095 PCT/IB2012/001699 -115 MS (ESI): 508 [M+H]*, 'H-NMR (DMSO-d 6 ): 6 (ppm) 12.23 (brs, 1H), 9.94 (s, 1H), 8.78 (s, 1H), 7.94 (d, 2H), 7.53 (d, 2H), 7.48 (m, 1H), 7.35 (m, 2H), 6.53 (br s, 1H), 6.21 (s, 1H), 2.61 (m, 2H), 2.51 (m, 1H), 2.42 (m, 1H), 2.40 br s, 6H), 2.24 (m, 1H), 2.16 (s, 3H), 2.05 (m, 1H), 1.56 (m, 1H), 1.28 (s, 9H). Biological Part Inhibition of Btk enzymatic activity The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepared with 8-point serial dilutions for the test compounds on a Thermo CatX workstation equipped with a Innovadyne Nanodrop Express. The assay plates were prepared by addition of 50 nI per well of compound solution in 90 % DMSO. The kinase reactions were started by stepwise addition of 4.5 pl per well of peptide/ATP-solution (4 pM FITC-Ahx TSELKKVVALYDYMPMNAND-NH2, 164 pM ATP) in kinase buffer (50mM HEPES, pH 7.5, 1mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mM beta glycerophosphate, and 10 pM sodium orthovanadate, 18 mM MgCl2, 1 mM MnCl2) and 4.5 pl per well of enzyme solution (6.4nM full-lenght human recombinant BTK) in kinase buffer. Kinase reactions were incubated at 300C for 60 minutes and subsequently terminated by addition of 16 pl per well of stop solution (100 mM HEPES pH 7.5, 5 % DMSO, 0.1 % Caliper coating reagent, 10 mM EDTA, and 0.015 % Brij35). Kinase reactions were analyzed on a Caliper LC3000 workstation by separating phosphorylated and unphosphorylated peptides and kinase activities were calculated from the amounts of newly formed phospho-peptide. Inhibition data were calculated by comparison to control reactions without enzyme (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations. Example Inhibition of Btk enzymatic activity IC50 [uM] Example 1 0.001 Example 2 0.004 Example 3 0.005 WO 2013/008095 PCT/IB2012/001699 -116 Example 4 0.002 Example 5 0.003 Example 6 0.002 Example 7 0.003 Example 8 0.003 Example 9 0.005 Example 10 0.015 Example 11 0.005 Example 12 0.004 Example 13 0.004 Example 14 0.016 Example 15 0.017 Example 16 0.002 Example 17 0.001 Example 18 0.006 Example 19 0.023 Example 20 0.006 Example 21 0.006 Example 22 0.008 Example 23 0.012 Example 24 0.023 Example 25 0.002 Example 26 0.035 Example 27 0.110 Example 28 0.046 Example 29 0.013 Example 30 0.006 Example 31 0.003 Example 32 0.007 Example 33 0.004 Example 34 0.034 Example 35 0.014 Example 36 0.004 Example 37 0.026 Example 38 0.027 Example 39 0.013 Example 40 0.019 Example 41 0.023 Example 42 0.030 Example 43 0.140 Example 44 0.017 WO 2013/008095 PCT/IB2012/001699 -117 Example 45 0.008 Example 46 0.017 Example 47 0.002 Example 48 0.007 Example 49 0.099 Example 50 0.047 Example 51 0.047 Example 52 0.024 Example 53 0.064 Example 54 0.024 Example 55 0.004 Example 56 0.002 Example 57 0.007 Example 58 0.016 Example 59 0.003 Example 60 0.008 Example 61 0.006 Example 62 0.002 Example 63 0.002 Example 64 0.015 Example 65 0.009 Example 66 0.012 Example 67 0.008 Inhibition of cellular Btk activity Alternatively, the present compounds might also be assessed for their capacity to inhibit Btk-dependent FcG receptor-induced IL-8 secretion in human cells. The human myeloid leukemia THP1 cell line (ATCC T1B202) was grown in RPMI 1640 medium supplemented with 10 % FCS and 15 nM 1, 25-dihydroxy Vitamin D3 during 4 days before use to induced myeloid differentiation. A sufficient number of tissue-culture grade 384-well plates was coated with human IgG of unknown specificity by incubating overnight at 40C with 40 pl/well of a 50 pg/ml IgG solution in PBS. On the day of the experiment, plates were washed 5 times with 80 pl water on a Molecular Devices Aquamax DW4 plate washer. Solutions of the test compounds in 90 % DMSO were added to each well on a Hamilton Microlab Star liquid handling station to 40 pl/well tissue culture medium and the total DMSO concentration was adjusted to 0.1 %. Differentiated THP1 cells were then added in 40 pl/well to reach a final density of 5'000 WO 2013/008095 PCT/IB2012/001699 -118 cells/well in 80 pl culture medium. After 24 hours, IL-8 secretion was measured in the supernatant by the IL-8 HTRF assay following the protocol of the vendor (CisBio international). Inhibition data were calculated by comparison to control cultures without IgG stimulus enzyme (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations. Example Inhibition of Btk cellular activity IC50 [uM] Example 3 0.027 Example 16 0.069 Example 24 0.094 Example 38 0.020 Example 62 0.071 Inhibition of Btk activity in blood Alternatively, the inhibitory activity of the present compounds in blood was assessed in the following in vitro B cell activation assay. Whole blood was collected from the abdominal aorta of anaesthetized adult male Lewis rats and was anticoagulated with 100 U/ml sodium heparin. Blood was then diluted to 50 % with high glucose DMEM (Amimed) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L glutamin, 50 mg/ml dextran 40 and 5% FCS (Fetaclone 1, Gibco). Then, 190 pl prediluted blood was mixed in 96 well U-bottomed microtiter plates (Nunc) with 10 pl of serial dilutions of test compounds in DMSO. Cultures were incubated at 370C, 5% C02 for 1 hour, then 30 pl of rat IL-4 (Beckton-Dickinson, final concentration 5 ng/ml) and goat anti-rat IgM (Serotec, final concentration 15 ug/ml) were added and the cultures were incubated for 24 hours. Activation of B cells was measured by flow cytometry after staining for the B cell subset with PE-Cy5-labeled anti-ratCD45RA (Beckton-Dickinson) and for the activation marker CD86 (PE-labeled anti-rat CD86 (Beckton-Dickinson). All staining procedures were performed at RT for 30 min in the dark in 96-deep well V bottomed microtiter plates (Corning) with BD Lysing Solution (Beckton-Dickinson). Cytometric data was acquired on a FACScalibur flow cytometer (BD Biosciences) and the subpopulation of lymphocytes were gated according to size and granularity and WO 2013/008095 PCT/IB2012/001699 -119 further analyzed for expression of CD45RA and the activation markers. Data for the inhibition of B cell activation were calculated from the percentage of cells positively stained for activation markers within the CD45RA positive population. Inhibition data were calculated by comparison to control cultures without anti-IgM and IL-4 (100 % inhibition) and without inhibitors (0 % inhibition). The concentration of inhibitor required for 50 % inhibition (IC50) was calculated from the inhibition in response to inhibitor concentrations. Example Inhibition of Btk activity in blood IC50 [uM] Example 2 0.072 Example 6 0.112 Example 17 0.100 Example 32 0.414 Example 58 0.179 Utilities Based for example upon the biological test results, compounds of the invention may generally be useful in the treatment of an indication selected from: Autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection; diseases in which antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable; including rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SOJIA), gout, pemphigus vulgaris, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjdgren's syndrome, autoimmune hemolytic anemia, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides, cryoglobulinem ia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), atherosclerosis, type 1 diabetes, type 2 diabetes, inflammatory bowel disease, ulcerative colitis, morbus Crohn, pancreatitis, glomerolunephritis, Goodpasture's syndrome, Hashimoto's thyroiditis, Grave's disease, antibody-mediated transplant rejection (AMR), graft versus host disease, B cell-mediated WO 2013/008095 PCT/IB2012/001699 - 120 hyperacute, acute and chronic transplant rejection; thromboembolic disorders, myocardial infarct, angina pectoris, stroke, ischemic disorders, pulmonary embolism; cancers of haematopoietic origin including but not limited to multiple myeloma; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Waldenstroem disease. In a further embodiment, the therapy is selected from a disease which may be treated by an antagonist of Bruton's tyrosine kinase. In another embodiment, the invention provides a method of treating a disease which is treated by the modulation of Btk- comprising administration of a therapeutically acceptable amount of a compound of formula (1) or a salt thereof. In a further embodiment, the disease is selected from the afore-mentioned lists Combinations The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents. The compounds of formula (1) may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent. For example, the compounds of formula (1) may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-0-(2 hydroxyethyl)-rapamycin, CC1779, ABT578, AP23573, AP23464, AP23675, AP23841, TAFA-93, biolimus-7 or biolimus-9; an ascomycin having immunosuppressive properties, e.g. ABT-281, ASM981, etc.; corticosteroids; cyclophosphamide; azathioprene; WO 2013/008095 PCT/IB2012/001699 - 121 methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N-benzyl-3,4-dihydroxy benzylidene-cyanoacetamide a-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide (Tyrphostin AG 490), prodigiosin 25-C (PNU156804), [4-(4'-hydroxyphenyl)-amino-6,7 dimethoxyquinazoline] (WHI-P1 31), [4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7 dimethoxyquinazoline] (WHI-P154), [4-(3',5'-dibromo-4'-hydroxylphenyl)-amino-6,7 dimethoxyquinazoline] WHI-P97, KRX-211, 3-{(3R,4R)-4-methyl-3-[methyl-(7H pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, in free form or in a pharmaceutically acceptable salt form, e.g. mono-citrate (also called CP-690,550), or a compound as disclosed in WO 04/052359 or WO 05/066156; sphingosine-1-phosphate receptor modulators such as FTY720 (fingolimod), or compounds disclosed in WO 2005/000833; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA 1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or a chemotherapeutic agent, e.g. paclitaxel, gemcitabine, cisplatinum, doxorubicin or 5 fluorouracil; or an anti-infectious agent. Further combination partners to a compound of formula (1) may be selected from a P13K inhibitor (e.g. pan, or alpha, beta, gamma, delta selectives), TNF inhibitors, ILibeta inhibitors, IL17 inhibitors, and inhibitors of IL6 or IL receptor. The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
WO 2013/008095 PCT/IB2012/001699 - 122 The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula (1) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula (1) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients. In one embodiment, the invention provides a product comprising a compound of formula (1) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by Btk kinases. Products provided as a combined preparation include a composition comprising the compound of formula (1) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (1) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit. In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (1) and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above. In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (1). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like. The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To WO 2013/008095 PCT/IB2012/001699 - 123 assist compliance, the kit of the invention typically comprises directions for administration. In the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent. Accordingly, the invention provides the use of a compound of formula (1) for treating a disease or condition mediated by Btk kinases, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by Btk , wherein the medicament is administered with a compound of formula (1). The invention also provides a compound of formula (1) for use in a method of treating a disease or condition mediated by Btk, wherein the compound of formula (1) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk , wherein the other therapeutic agent is prepared for administration with a compound of formula (1). The invention also provides a compound of formula (1) for use in a method of treating a disease or condition mediated by Btk , wherein the compound of formula (1) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by Btk, wherein the other therapeutic agent is administered with a compound of formula (1).

权利要求:
Claims (17)
[1] 1. A compound of formula (1) or a pharmaceutically acceptable salt thereof; R5 0 R3 R4'N R2 R1 X-R10 N N H (i) wherein, R1 is hydrogen, C1-C6 alkyl optionally substituted by hydroxy; R2 is hydrogen or halogen; R3 is hydrogen or halogen; R4 is hydrogen, R5 is phenyl optionally substituted by halogen; SF 5 ; NR6R7; hydroxy; C1-C6 alkoxy; C1 C6 alkenyl; C1-C6 alkyl carbonyl; C1-C6 alkyl optionally substituted by hydroxy, halogen, or C1-C6 alkoxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, or C1-C6 alkyl optionally substituted by halogen; or R5 is a 4 - 14 membered mono- or bicyclic heterocyclyl or heteroaryl ring system comprising 1, 2 or 3 heteroatoms selected from N, S and 0 that ring being optionally substituted by halogen; hydroxy; C1-C6 alkoxy optionally substituted by hydroxy or halogen; or C1-C6 alkyl optionally substituted by hydroxy or halogen; or R4 and R5 together with the atoms to which they are bound form a piperidone ring, optionally comprising an annulated phenyl ring, any such ring being optionally substituted by C1-C6 alkyl, C1-C6 alkoxy, or C3-C6 cycloalkyl each of which substitution member may optionally be substituted by halogen or hydroxy; R6 and R7 are independently selected from hydrogen or C1-C6 alkyl; or R6 and R7 together with the nitrogen atom to which they are bound form a 4 - 8 membered saturated azacycloalkane ring, optionally substituted by halogen, hydroxy or C1-C6 alkyl; WO 2013/008095 PCT/IB2012/001699 -125 K (CH2)q X is 0, S(O), wherein n is 0, 1 or 2, or 0 wherein q is 2 or 3, and R10 is absent; or X is CH or N; and R10 is hydrogen, hydroxy, -NR6R7, -CO-R11, -S(O)p-R12 wherein p is 1 or 2, R 11 is C1-C alkyl optionally substituted by hydroxy, cyano, halogen, carboxy or C1-C6 alkoxy carbonyloxy; or NR6R7; and R12 is C1-C alkyl or NR6R7.
[2] 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen; R5 is phenyl substituted by halogen; C1-C alkoxy; C1-C alkyl optionally substituted by halogen or hydroxy; or C3-C cycloalkyl optionally substituted by halogen, hydroxy, or C1-C alkyl optionally substituted by halogen; X is 0, O (CH2 )q S(O), wherein n is 0, 1 or 2, or 0 wherein q is 2 or 3, and R10 is absent; and the remaining variables are as defined in claim 1.
[3] 3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C cycloalkyl or C1-C alkyl optionally substituted by hydroxy; X is 0, O (CH2 )q S(O), wherein n is 0, 1 or 2, or 0 wherein q is 2 or 3, and R10 is absent; and the remaining variables are as defined in claim 1.
[4] 4. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen; R5 is phenyl substituted by halogen; C1-C alkoxy; C1-C alkyl optionally substituted by halogen or hydroxy; or C3-C cycloalkyl optionally substituted by halogen, hydroxy, or C1-C alkyl optionally substituted by halogen; X WO 2013/008095 PCT/IB2012/001699 - 126 stands for 0 and R10 is absent; or X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined in claim 1.
[5] 5. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen; R5 is phenyl substituted by C1-C6 alkoxy; C1-C6 alkyl optionally substituted by halogen or hydroxy; or C3-C6 cycloalkyl optionally substituted by halogen, hydroxy, or C1-C6 alkyl optionally substituted by halogen; X stands for N, R10 is hydrogen or -CO-R1 1, R11 stands for NR6R7 wherein R6 and R7 are independently hydrogen or methyl; and the remaining variables are as defined in claim 1.
[6] 6. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 is hydrogen, R5 is azetidine optionally substituted by C1-C6 alkoxy, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined in claim 1.
[7] 7. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined in claim 1.
[8] 8. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen orfluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy in the 6 position of said isoquinolin-ring, X stands for N, and R10 is hydrogen or -CO-R1 1, and the remaining variables are as defined in claim 1.
[9] 9. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently WO 2013/008095 PCT/IB2012/001699 - 127 hydrogen or fluoro, R4 is hydrogen, R5 is azetidine optionally substituted by C1-C6 alkoxy, X stands for 0, and the remaining variables are as defined in claim 1.
[10] 10. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen, methyl or hydroxymethyl , R2 and R3 are independently hydrogen or fluoro, R4 together with R5 is a 3,4-dihydro-2H-isoquinolin-1-one optionally substituted by C3-C6 cycloalkyl or C1-C6 alkyl optionally substituted by hydroxy, X stands for 0, and the remaining variables are as defined claim 1.
[11] 11. A compound of claim 1, or a pharmaceutically acceptable salt thereof, which is selected from: 4-(4-{5-Fluoro-3-[4-(1 -fluoro-cyclopropyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[(3,3-Dimethyl-2,3-d ihydro-benzofuran-6-carbonyl)-amino]-5-fluoro-2-methyl phenyl}-7H-pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[(5-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-2-carbonyl) amino]-phenyl}-7H-pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-isopropyl-methyl-amino)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2'3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 3-Methyl-1 H-indole-6-carboxylic acid {3-[6-(1 -dimethylcarbamoyl-1,2,3,6-tetrahydro pyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-(4-{5-Fluoro-3-[4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-2-methyl-3-(4-piperidin-1-yl-benzoylamino)-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-3-(isopropenyl-benzoylamino)-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[4-(1 -trifluoromethyl-cyclopropyl)-benzoylamino]-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[5-Fluoro-3-(4-isopropoxy-benzoylamino)-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, WO 2013/008095 PCT/IB2012/001699 - 128 4-(4-{5-Fluoro-3-[4-pentafluorothio-benzoylamino]-2-methyl-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3, 6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-(2-methoxy-1,1-dimethyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[4-(1-methoxy-1-methyl-ethyl)-benzoylamino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 1-Methyl-1 H-pyrrolo[2,3-b]pyridine-6-carboxylic acid {3-[6-(1-dimethyl-carbamoyl-1,2,3,6 tetrahyd ro-pyrid in-4-yl)-7 H-pyrrolo[2,3-d]pyrimid in-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-{4-[3-(4-Dimethylamino-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylamino]-2-hydroxymethyl-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-2-hydroxymethyl-phenyl]-7H-pyrrolo[2,3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-2-methyl-3-[4-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)-benzoylamino] phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Acetyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6 yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-4-fluoro-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl} 3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{4-Fluoro-3-[4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoylamino]-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-hydroxymethyl phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yl]-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-benzamide, WO 2013/008095 PCT/IB2012/001699 - 129 4-tert-Butyl-N-{3-[6-(1,4-d ioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hyd roxy-cyclohex- 1 -enyl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl] 2-methyl-phenyl}-benzamide, 4-{4-[3-(4-Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2'3 d]pyrimidin-6-yl}-3,6-dihydro-2 H-pyridine-1-carboxylic acid dimethylamide, 4-Cyclopropyl-N-(5-fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-phenyl)-benzamide, Acetic acid 2-(4-{4-[3-(4-cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3, 6-dihydro-2 H-pyridin-1-yl)-2-oxo-ethyl ester, 4-Cyclopropyl-N-(5-fluoro-3-{6-[1-(2-hydroxy-actyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H pyrrolo[2,3-d] pyrimid in-4-yl}-2-methyl-phenyl)benzamide, N-(3-{6-[1-(2-Cyano-acetyl)-1,2,3, 6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4 yl}-5-fluoro-2-methyl-phenyl)-4-cyclopropyl-benzamide, N-(5-Fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H pyrrolo[2,3-d]pyrimidin-4-yl}-phenyl)-4-(pentafluoro-sulfanyl)-benzamide, Acetic acid 2-[4-(4-{5-fluoro-2-methyl-3-[4-(pentafluoro-sulfanyl)-benzoylam ino]-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2 H-pyridin-1-yl]-2-oxo-ethyl ester, N-(5-Fluoro-3-{6-[1-(2-hydroxy-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3 d]pyrimidin-4-yl}-2-methyl-phenyl)-4-(pentafluoro-sulfanyl)-benzamide, 4-{4-[3-(4-tert-Butyl-benzoylamino)-2-(tert-butyl-diphenyl-silanyloxymethyl)-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3, 6-dihydro-2 H-pyridine-1-carboxylic acid tert-butyl ester, 4-tert-Butyl-N-(3-{6-[1-(2-fluoro-acetyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H-pyrrolo[2,3 d]pyrimidin-4-yl}-2-hydroxymethyl-phenyl)-benzamide, 4-(4-{5-Fluoro-3-[2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzoylamino]-2-methyl-phenyl} 7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-phenyl}-benzamide, 4-{4-[3-(4-tert-Butyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin 6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{5-fluoro-3-[6-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yl]-2-methyl-phenyl}-benzamide, WO 2013/008095 PCT/IB2012/001699 -130 4-tert-Butyl-N-{3-[6-(1 -dimethylsulfamoyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d] pyrim id in-4-yl]-5-fluoro-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1 -methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-7H-pyrrolo[2,3 d] pyrim id in-4-yl]-2-methyl-phenyl}-benzamide, 4-{4-[3-(6-tert-Butyl-1-oxo-3,4-dihydro-1 H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-{4-[3-(6-Cyclopropyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxymethyl-phenyl] 7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{2-Hydroxymethyl-3-[6-(1-hydroxy-1-methyl-ethyl)-1-oxo-3,4-dihydro-1 H-isoquinolin 2-yl]-phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hydroxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro 2-methyl-phenyl}-benzamide, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl phenyl}-4-dimethylamino-benzamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl -N-{2-methyl-3-[6-(3,6-dihydro-1-oxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-phenyl}-benzamide, 4-tert-Butyl -N-{3-[6-(3,6-dihydro-1,1-dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d]pyrimidin-4-yl]-2-methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hydroxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hydroxymethyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 hydroxymethyl-phenyl}-benzamide, 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-amino]-5-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{5-Fluoro-3-[(3-isopropoxy-azetidine-1-carbonyl)-amino]-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, WO 2013/008095 PCT/IB2012/001699 - 131 5-Fluoro-1,3-dihydro-isoindole-2-carboxylic acid {3-[6-(1-dimethylcarbamoyl-1,2,3,6 tetrahyd ro-pyrid in-4-yl)-7 H-pyrrolo[2,3-d]pyrimid in-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-[4-(5-Fluoro-2-methyl-3-{[3-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-azetidine-1 carbonyl]-amino}-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1 carboxylic acid dimethylamide, 3-tert-Butoxy-azetidine-1-carboxylic acid {3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-amide, 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-amino]-4-fluoro-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-(4-{3-[(3-tert-Butoxy-azetidine-1-carbonyl)-amino]-4-fluoro-2-methyl-phenyl}-7H pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide, 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, 4-tert-Butyl-N-{3-[6-(4-hydroxy-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide, and 4-tert-Butyl-N-{3-[6-(4-dimethylamino-cyclohex-1-enyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2 methyl-phenyl}-benzamide.
[12] 12. A compound claim 1, or a pharmaceutically acceptable salt thereof, which is selected from: 4-{4-[3-(4-Acetyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6 yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide; 4-{4-[3-(4-Cyclopropyl-benzoylamino)-4-fluoro-phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl} 3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide; 4-(4-{4-Fluoro-3-[4-(2-hydroxy-1,1-dimethyl-ethyl)-benzoylamino]-phenyl}-7H-pyrrolo[2,3 d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide; N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide; N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-hydroxymethyl phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide; 4-tert-Butyl-N-{3-[6-(3,6-dihydro-2H-thiopyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide; WO 2013/008095 PCT/IB2012/001699 - 132 4-tert-Butyl-N-{5-fluoro-2-methyl-3-[6-(3,6-dihydro-1 -oxido-2H-thiopyran-4-yl)-7H pyrrolo[2,3-d] pyrimid in-4-yl]-phenyl}-benzamide; 4-tert-Butyl-N-{3-[6-(3,6-dihydro-1,1 -dioxido-2H-thiopyran-4-yl)-7H-pyrrolo[2,3 d] pyrim id in-4-yl]-5-fluoro-2-methyl-phenyl}-benzamide; 4-tert-Butyl-N-{3-[6-(1,4-d ioxa-spiro[4.5]dec-7-en-8-yl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl]-5 fluoro-2-methyl-phenyl}-benzamide; 4-tert-Butyl-N-{5-fluoro-3-[6-(4-hyd roxy-cyclohex- 1 -enyl)-7H-pyrrolo[2,3-d] pyrimid in-4-yl] 2-methyl-phenyl}-benzamide; 4-{4-[3-(4-Cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H-pyrrolo[2'3 d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide; 4-Cyclopropyl-N-(5-fluoro-2-methyl-3-{6-[1-(pyrrolidine-1-carbonyl)-1,2,3,6-tetrahydro pyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-phenyl)-benzamide; Acetic acid 2-(4-{4-[3-(4-cyclopropyl-benzoylamino)-5-fluoro-2-methyl-phenyl]-7H pyrrolo[2,3-d]pyrimidin-6-yl}-3,6-dihydro-2H-pyridin-1-yl)-2-oxo-ethyl ester; and 4-Cyclopropyl-N-(5-fluoro-3-{6-[1-(2-hydroxy-actyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-7H pyrrolo[2,3-d] pyrimid in-4-yl}-2-methyl-phenyl)benzamide.
[13] 13. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 12 and one or more pharmaceutically acceptable carriers.
[14] 14. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof and one or more therapeutically active co-agents.
[15] 15. A method of modulating Btk activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.
[16] 16. A compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, for use as a medicament.
[17] 17. Use of a compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease mediated by Btk.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2012282229B2|2015-05-07|Novel pyrrolo pyrimidine derivatives

---

JP6667573B2|2020-03-18|New aminopyrimidine derivatives

---

AU2014327235B2|2018-02-08|New 3-|-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors

---

AU2014400628A1|2017-01-19|Aminopyridazinone compounds as protein kinase inhibitors

---

CA3019145A1|2017-10-05|Pyrrolotriazine compounds as tam inhibitors

---

TW201206930A|2012-02-16|Tetrahydro-pyrido-pyrimidine derivatives

---

KR20170137127A|2017-12-12|Chromene derivatives as phosphoinositide 3-kinase inhibitors

---

CA2831929A1|2012-10-04|Pyrazolo pyrimidine derivatives

---

JP6186440B2|2017-08-23|Dihydropyrrolidinopyrimidines as kinase inhibitors

---

TW201425313A|2014-07-01|Novel pyrrolo pyrimidine derivatives

同族专利:

---

公开号 | 公开日

---

ES2548414T3|2015-10-16|

---

JP6145451B2|2017-06-14|

---

MX2014000338A|2014-05-01|

---

US9233111B2|2016-01-12|

---

JP2014520793A|2014-08-25|

---

US20140243306A1|2014-08-28|

---

WO2013008095A1|2013-01-17|

---

BR112014000314A2|2017-01-10|

---

AU2012282229B2|2015-05-07|

---

EP2729466A1|2014-05-14|

---

EP2729466B1|2015-08-19|

---

EA201490229A1|2014-05-30|

---

CN103732596B|2016-06-01|

---

CN103732596A|2014-04-16|

---

KR20140058543A|2014-05-14|

---

CA2841111A1|2013-01-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

JP2002517396A|1998-06-04|2002-06-18|アボット・ラボラトリーズ|Anti-inflammatory compounds that inhibit cell adhesion|

---

PA8474101A1|1998-06-19|2000-09-29|Pfizer Prod Inc|PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS|

---

US6303652B1|1998-08-21|2001-10-16|Hughes Institute|BTK inhibitors and methods for their identification and use|

---

GB2345868A|1999-01-23|2000-07-26|Martin Hodgson|Self adhesive magnetic or electromagnetic tapes|

---

WO2000075145A1|1999-06-03|2000-12-14|Abbott Laboratories|Cell adhesion-inhibiting antiinflammatory compounds|

---

GB0005345D0|2000-03-06|2000-04-26|Mathilda & Terence Kennedy Ins|Methods of treating sepsis septic shock and inflammation|

---

WO2002038797A2|2000-10-23|2002-05-16|Bristol-Myers Squibb Company|Modulators of bruton's tyrosine kinase, their identification and use|

---

PT1337527E|2000-11-07|2009-12-10|Novartis Ag|Indolylmaleimide derivatives as protein kinase c inhibitors|

---

EP1217000A1|2000-12-23|2002-06-26|Aventis Pharma Deutschland GmbH|Inhibitors of factor Xa and factor VIIa|

---

GB0119249D0|2001-08-07|2001-10-03|Novartis Ag|Organic compounds|

---

WO2004078163A2|2003-02-28|2004-09-16|Transform Pharmaceuticals, Inc.|Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen|

---

TW200918046A|2002-04-03|2009-05-01|Novartis Ag|Indolylmaleimide derivatives|

---

EP2322203A3|2002-10-29|2011-07-27|Genentech, Inc.|Compositions and methods for the treatment of immune related diseases|

---

CA2506432A1|2002-12-09|2004-06-24|Robert A. Kirken|Methods for selectively inhibiting janus tyrosine kinase 3 |

---

EP1473039A1|2003-05-02|2004-11-03|Centre National De La Recherche Scientifique |Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis|

---

AU2004251146A1|2003-05-19|2005-01-06|Irm, Llc|Immunosuppressant compounds and compositions|

---

US7393848B2|2003-06-30|2008-07-01|Cgi Pharmaceuticals, Inc.|Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds|

---

GB2432834A|2004-01-12|2007-06-06|Cytopia Res Pty Ltd|Selective Kinase Inhibitors|

---

PE20051092A1|2004-01-29|2006-01-20|Novartis Ag|PYROLO-PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES|

---

WO2006017443A2|2004-08-02|2006-02-16|Osi Pharmaceuticals, Inc.|Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds|

---

GB0420719D0|2004-09-17|2004-10-20|Addex Pharmaceuticals Sa|Novel allosteric modulators|

---

WO2006099075A2|2005-03-10|2006-09-21|Cgi Pharmaceuticals, Inc.|Certain substituted amides, method of making, and method of use thereof|

---

US20080188483A1|2005-03-15|2008-08-07|Irm Llc|Compounds and Compositions as Protein Kinase Inhibitors|

---

GT200600197A|2005-05-13|2007-03-28||COMPOUNDS AND COMPOSITIONS AS PROTEIN QUINASA INHIBITORS|

---

ES2473341T3|2005-05-20|2014-07-04|Methylgene Inc|Inhibitors of VEGF receptor and HGF receptor signaling|

---

US20070129364A1|2005-12-07|2007-06-07|Han-Qing Dong|Pyrrolopyridine kinase inhibiting compounds|

---

EP2348023B9|2005-12-13|2017-03-08|Incyte Holdings Corporation|Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors|

---

ES2395386T3|2005-12-21|2013-02-12|Abbott Laboratories|Antiviral compounds|

---

CA2635899A1|2006-01-19|2007-07-26|Osi Pharmaceuticals, Inc.|Fused heterobicyclic kinase inhibitors|

---

US7678818B2|2006-02-07|2010-03-16|Hoffmann-La Roche Inc.|Anthranilamide and 2-amino-heteroarene-carboxamide compounds|

---

JO3235B1|2006-05-26|2018-03-08|Astex Therapeutics Ltd|Pyrrolopyrimidine compounds and their uses|

---

DE602007008237D1|2006-06-08|2010-09-16|Amgen Inc|BENZAMID DERIVATIVES AND ASSOCIATED USES|

---

DE102006033109A1|2006-07-18|2008-01-31|Grünenthal GmbH|Substituted heteroaryl derivatives|

---

US20100160292A1|2006-09-11|2010-06-24|Cgi Pharmaceuticals, Inc|Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors|

---

AR063946A1|2006-09-11|2009-03-04|Cgi Pharmaceuticals Inc|CERTAIN REPLACED PIRIMIDINS, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.|

---

PT2526771T|2006-09-22|2017-02-27|Pharmacyclics Llc|Inhibitors of bruton's tyrosine kinase|

---

SG10201508035TA|2007-03-28|2015-10-29|Pharmacyclics Inc|Inhibitors of bruton's tyrosine kinase|

---

SI2134374T1|2007-03-14|2014-03-31|Bionsil S.R.L. In Liquidazione|Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours|

---

WO2008144253A1|2007-05-14|2008-11-27|Irm Llc|Protein kinase inhibitors and methods for using thereof|

---

US20100190777A1|2007-07-17|2010-07-29|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

JP5587193B2|2007-10-23|2014-09-10|エフ．ホフマン−ラロシュアーゲー|Novel kinase inhibitors|

---

US20090118276A1|2007-11-02|2009-05-07|Wyeth|Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors|

---

ES2462642T3|2007-12-14|2014-05-26|F. Hoffmann-La Roche Ag|New derivatives of imidazo [1,2-a] pyridine and imidazo [1,2-b] pyridazine|

---

US7683064B2|2008-02-05|2010-03-23|Roche Palo Alto Llc|Inhibitors of Bruton's tyrosine kinase|

---

PE20091846A1|2008-05-19|2009-12-16|Plexxikon Inc|PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS|

---

US8158636B2|2008-05-19|2012-04-17|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

BRPI0913879A2|2008-07-02|2019-09-24|Hoffmann La Roche|phenylpyrazinones as kinase inhibitors|

---

ES2660418T3|2008-07-16|2018-03-22|Pharmacyclics Llc|Bruton tyrosine kinase inhibitors for the treatment of solid tumors|

---

US20100063047A1|2008-09-10|2010-03-11|Kalypsys, Inc.|Aminopyrimidine inhibitors of histamine receptors for the treatment of disease|

---

WO2010036316A1|2008-09-24|2010-04-01|Yangbo Feng|Urea and carbamate compounds and analogs as kinase inhibitors|

---

JP5731978B2|2008-09-26|2015-06-10|インテリカイン， エルエルシー|Heterocyclic kinase inhibitor|

---

CL2009001884A1|2008-10-02|2010-05-14|Incyte Holdings Corp|Use of 3-cyclopentyl-3- [4- -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.|

---

US20100261776A1|2008-11-07|2010-10-14|The Research Foundation Of State University Of New York|Bruton's tyrosine kinase as anti-cancer drug target|

---

WO2010068806A1|2008-12-10|2010-06-17|Cgi Pharmaceuticals, Inc.|Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer|

---

EP2416772A1|2009-04-06|2012-02-15|PTC Therapeutics, Inc.|Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent|

---

EP2417133A1|2009-04-06|2012-02-15|PTC Therapeutics, Inc.|Compounds and methods for antiviral treatment|

---

CN102482277B|2009-05-05|2017-09-19|达纳-法伯癌症研究所有限公司|Epidermal growth factor receptor inhibitor and the method for treating obstacle|

---

WO2011029043A1|2009-09-04|2011-03-10|Biogen Idec Ma Inc.|Heteroaryl btk inhibitors|

---

HUE043522T2|2009-09-04|2019-08-28|Biogen Ma Inc|Bruton's tyrosine kinase inhibitors|

---

EP2569316B1|2010-05-12|2014-04-23|Abbvie Inc.|Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases|

---

US20120071497A1|2010-06-03|2012-03-22|Pharmacyclics, Inc.|Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase|

---

EP2632898A4|2010-10-29|2014-04-02|Biogen Idec Inc|Heterocyclic tyrosine kinase inhibitors|

---

WO2013003629A2|2011-06-28|2013-01-03|Pharmacyclics, Inc.|Methods and compositions for inhibition of bone resorption|

---

WO2013008095A1|2011-07-08|2013-01-17|Novartis Ag|Novel pyrrolo pyrimidine derivatives|

---

WO2013023084A2|2011-08-09|2013-02-14|Fred Hutchinson Cancer Research Center|Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells|

---

DE102011111400A1|2011-08-23|2013-02-28|Merck Patent Gmbh|Bicyclic heteroaromatic compounds|

---

CA3110966A1|2011-10-19|2013-04-25|Pharmacyclics Llc|Use of inhibitors of bruton's tyrosine kinase |

---

WO2013071865A1|2011-11-14|2013-05-23|Centaurus Biopharma Co., Ltd.|Kinase modulating compounds, compositions containing the same and use thereof|WO2013008095A1|2011-07-08|2013-01-17|Novartis Ag|Novel pyrrolo pyrimidine derivatives|

---

CN104662018B|2012-04-20|2017-10-24|阿迪维纳斯治疗有限公司|Substituted Heterobicyclic compounds, composition and its medical applications|

---

WO2013157021A1|2012-04-20|2013-10-24|Advinus Therapeutics Limited|Bicyclic compounds, compositions and medicinal applications thereof|

---

WO2014018567A1|2012-07-24|2014-01-30|Pharmacyclics, Inc.|Mutations associated with resistance to inhibitors of bruton's tyrosine kinase |

---

EA028756B1|2013-04-25|2017-12-29|Бэйджин, Лтд.|Fused heterocyclic compounds as protein kinase inhibitors|

---

CN108715615B|2013-09-13|2020-11-27|百济神州生物科技有限公司|anti-PD 1 antibodies and their use as therapeutic and diagnostic agents|

---

US9512084B2|2013-11-29|2016-12-06|Novartis Ag|Amino pyrimidine derivatives|

---

CN105939717B|2013-12-02|2019-09-13|药品循环有限责任公司|The method for treating and preventing the chronic graft versus host disease of allo-antibody driving|

---

AR102177A1|2014-10-06|2017-02-08|Merck Patent Gmbh|HETEROARILO COMPOUNDS AS BTK INHIBITORS AND USES OF THE SAME|

---

PE20190710A1|2014-10-24|2019-05-17|Squibb Bristol Myers Co|INDOL CARBOXAMIDE COMPOUNDS USED AS KINASE INHIBITORS|

---

WO2016079669A1|2014-11-19|2016-05-26|Novartis Ag|Labeled amino pyrimidine derivatives|

---

AR102871A1|2014-12-03|2017-03-29|Pharmacyclics Llc|FIBROSIS TREATMENT METHODS|

---

EP3042903B1|2015-01-06|2019-08-14|Impetis Biosciences Ltd.|Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof|

---

US20170174671A1|2015-12-17|2017-06-22|Incyte Corporation|Heterocyclic compounds as immunomodulators|

---

WO2018033853A2|2016-08-16|2018-02-22|Beigene, Ltd.|Crystalline form of -7--2--4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof|

---

BR112019005337A2|2016-09-19|2019-08-27|Mei Pharma Inc|combination therapy|

---

ES2874756T3|2016-12-22|2021-11-05|Incyte Corp|Triazolo [1,5-A] pyridine derivatives as immunomodulators|

---

BR112019012957A2|2016-12-22|2019-11-26|Incyte Corp|tetrahydroimidazo [4,5-c] pyridine derivatives as inducers of internalization of pd-11|

---

MX2019007416A|2016-12-22|2019-12-11|Incyte Corp|Benzooxazole derivatives as immunomodulators.|

---

CN110072865B|2017-02-08|2022-02-11|中国医药研究开发中心有限公司|Pyrrolo-aromatic heterocyclic compounds, preparation method and medical application thereof|

---

JP2021519266A|2018-03-26|2021-08-10|ノバルティス アーゲー|3-Hydroxy-N-phenyl) pyrrolidine-1-carboxamide derivative|

---

JP2021519278A|2018-03-26|2021-08-10|ノバルティス アーゲー|N-phenyl) benzamide derivative|

---

CN112135824A|2018-03-30|2020-12-25|因赛特公司|Heterocyclic compounds as immunomodulators|

---

JP2021524842A|2018-05-11|2021-09-16|インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ|Tetrahydro-imidazole [4,5-C] pyridine derivative as PD-L1 immunomodulator|

---

CN111704617A|2020-06-15|2020-09-25|嘉兴特科罗生物科技有限公司|Small molecule compound|

法律状态:
2015-09-10| MK25| Application lapsed reg. 22.2i(2) - failure to pay acceptance fee|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161505560P| true| 2011-07-08|2011-07-08||

---

US61/505,560||2011-07-08||

---

PCT/IB2012/001699|WO2013008095A1|2011-07-08|2012-07-07|Novel pyrrolo pyrimidine derivatives|

---